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ABSTRACT 
Background 
Chronic kidney disease (CKD) is an increasingly important cause of morbidity and 
mortality worldwide and it is in developing countries, such as South Africa, that bears 
the greatest portion of the burden of CKD.  Anaemia is a frequent complication of 
CKD that has significant implications in terms of progression of the disease, as well 
as on the quality of life. It is for that reason that we have reviewed the demographics 
and causes of CKD; as well the prevalence, contributors to and management of 
anaemia of the chronic dialysis population at Chris Hani Baragwanath Academic 
Hospital (CHBAH). 
Methods 
A retrospective review of the chronic dialysis population at CHBAH in January 2012 
was conducted. Patients’ records, using both paper-based records and electronic 
records in the form of Bara Active Renal Tracking (BART) programme were 
analyzed. Data was captured electronically using the REDCap (Research Electronic 
Data Capture) tool and exported to Microsoft Excel and GraphPad InStat 
programmes to compile the statistics, figures and tables.  Chi-square test was used 
for comparisons between groups with categorical variables and an unpaired t test 
was used to compare groups with normally distributed variables. To compare 
proportions between the two groups a Fishers exact test was performed. A P-value 
of < 0.05 was taken as significant. 
Results 
The chronic dialysis population consisted of a total of 140 patients in January 2012. 
Based on exclusion criteria, 4 patients were excluded. The mean age of the patients 
v 
 
was 45 ± 13 years, with the peritoneal dialysis (PD) cohort being slightly older as 
compared to the haemodialysis (HD) cohort. A larger proportion of the cohort were 
male (56.6%) and 87% percent of the cohort were Black patients.  
The cause of CKD was unknown in the majority of the patients – 72% in the HD 
group and 56% in the PD group. The other causes noted were hypertension (17%), 
primary glomerulonephritis (5.9%), and diabetes mellitus (5.9%). None of the causes 
of CKD were associated with more severe rates or degrees of anaemia. 
Suboptimal haemoglobin levels were present in 40% of the patients, with higher 
rates and increased severity of anaemia noted among the patients on haemodialysis. 
Among the HD patients, those patients with an arteriovenous fistula or a permanent 
cuffed venous catheter had higher haemoglobin levels. Other factors associated with 
lower levels of haemoglobin included younger age of the patients, the presence of 
hyperparathyroidism, sepsis and inflammation (indicated by C - reactive protein and 
ferritin levels) and Hepatitis C seropositivity. 
Approximately 85 % of the patients were receiving erythropoiesis stimulating agents, 
with higher rates and doses noted in the HD group, as compared to the PD group 
(p˂0.001). Only 40% of the HD patients and 16% of the PD patients received 
intravenous iron as part of the regular prescription. 
Discussion 
Our findings that the mean age in the chronic dialysis population CHBAH is 
substantially lower than in developed countries is in keeping with the finding that that 
end stage renal disease (ESRD) patients on dialysis are younger in the developing 
world, where the delay in detection of renal disease and the failure to institute timely 
preventative measures results in a faster deterioration of renal function and the 
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development of ESRD at a young age. A factor that may also affect the mean age of 
our study population are the selection criteria for patients to be enrolled on the 
chronic dialysis programme in the public sector in South Africa. The patients need to 
qualify for a renal transplant.  In our population and in the developing world  the 
cause in a large proportion of patients with ESRD remains unknown because of late 
presentation or referral of patients, inadequacy of medical care facilities and 
shrunken kidneys, as is represented by the more than 65% of patients in the study, 
for whom there was no attributable cause of ESRD stated.  
Suboptimal correction of anaemia is present in a significant portion of our chronic 
dialysis population with a variety of contributing factors. This complication is 
inadequately managed, both in terms of addressing contributing factors and the 
prescription of the correct treatment. Rates of erythropoietin use in our population 
were comparable to international studies; however hyporesponsiveness to ESA 
therapy in our population is a concern based on the suboptimal rates of usage of 
intravenous iron. 
Conclusion 
CKD is a major problem in South Africa, where a double burden of disease is 
present- diseases of lifestyle and infectious diseases. Renal replacement therapy is 
a scarce resource and complications such as anaemia need to be aggressively 
managed in patients on this therapy, so as to maximise the benefit and improve 
outcomes. In conclusion, there is much room for improvement in the management of 
this grave consequence of ESRD by more stringent application of the available 
recent international and local guidelines. 
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CHAPTER 1: Literature review 
1.1 History of Chronic Kidney Disease 
 
The history of kidney disease dates back to the origins of civilization. Renal disease 
has been mentioned in the writings, scrolls and tablets of ancient civilizations, 
including those of the Mesopotamians, ancient Egyptians, Greeks and the Romans. 
They contain references to persons we might now, in retrospect, surmise were 
sufferers of chronic kidney disease (CKD). The Greek physician,  Areteus of 
Cappadocia (81–138 CE), now remembered mainly for describing diabetes mellitus 
as the melting of the flesh into the urine, also wrote about hydronephrosis, renal 
colic, strangury, post obstructive diuresis, oedema, and the anaemia of renal 
insufficiency (1). Even the Bible mentions the kidneys more than 30 times. In this 
text, the human kidneys are described figuratively as the location of temperament, 
emotions, prudence, vigour, and wisdom (2). It was Galen of Pergamos (second 
century AD), who correctly proposed that blood is cleared by the kidneys (3). Urine 
was the first bodily fluid to be examined and has, throughout the history of medicine, 
continuously been studied as a means to comprehending inner bodily functions. 
 
During the eighteenth and nineteenth centuries the concept of renal function and 
dysfunction began to emerge. Well known English physician, Richard Bright, in his 
1827 publication “Reports of medical cases selected with the view of illustrating the 
symptoms and cure of disease by reference to morbid anatomy” made observations 
and statements regarding ‘irritation of the kidneys’. He described observations of 
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nocturia, fading of the healthy countenance, a sense of lassitude and depression. He 
also noted pericarditis, blurring of vision and seizures (4).  In the nineteenth and 
twentieth centuries, studies by chemists of levels of urea and creatinine expanded 
that understanding.  
 
1.2 Chronic Kidney Disease 
1.2.1 Burden of disease 
 
Chronic kidney disease (CKD) is an increasingly important cause of morbidity and 
mortality worldwide. Looking at worldwide figures, CKD as a cause of mortality has 
almost doubled in the twenty years spanning 1990 to 2010 (5).  In reality, it is the 
developing countries, such as South Africa, that are bearing the greatest portion of 
the burden of CKD (6). This is because the prevalence of both communicable 
diseases (e.g. human immunodeficiency virus (HIV)) and non-communicable 
diseases (e.g. hypertension and diabetes mellitus)  responsible for causing CKD, are 
increasing (6). Proof of the escalating burden of these conditions is demonstrated by 
the fact that of the total of 572 673 deaths registered at the South African 
Department of Home Affairs in 2009, 20 523 were attributed to diabetes mellitus, 
15 386 were attributed to hypertension and 17 570 to HIV disease. All of these 
figures have increased as demonstrated in table 1,as cause of deaths from 2007 to 
2009 (7). The general impression is that CKD is 3-4 times more common in Africa as 
compared to developed countries; however there are a lack of registries and 
databases to confirm this (8).  In sub Saharan Africa CKD affects mainly young 
adults aged between 20 - 50 years and in  the majority of cases is attributed to 
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hypertension and glomerular diseases (9).  According to the South African Dialysis 
and Transplantation Registry, hypertension was listed as the most common cause of 
end stage renal disease (ESRD) in black South Africans, causing close to 35% 
percent of the ESRD in this population during the six years spanning  (10). 
 
Table 1: Causes of death in South Africa (2007-2009) 
Causes of Death(based on the 10th 
revision, International Classification 
of Diseases,1992) 
2009 2008 2007 
 Rank      number       % Rank        number     % Rank     number      % 
Tuberculosis 1           69 003     12.0 1           75 238     12.6 1        77 091     12.8 
Influenza and pneumonia 2           42 964       7.5 2           45 806       7.7 2        50 035       8.3 
Intestinal infectious disease 3           30 675       5.4 3           39 512       6.6 3        37 553       6.2 
Other forms of heart disease 4           26 462       4.6 4           26 306       4.4 4        26 144       4.3 
Cerebrovascular disease 5           24 835       4.3 5           24 453       4.1 5        25 438       4.2 
Diabetes Mellitus 6           20 523       3.6 6           19 622       3.3 6        20 215       3.3 
HIV 7           17 570       3.1 7           15 172       2.5 9        13 571       2.2 
Hypertensive diseases 8           17 386       2.7 10         14 230       2.4 10      13 429       2.2 
Chronic lower respiratory disease 9           14 184       2.5 9           14 322       2.4 7        15 386       2.5 
Certain disorders involving the 
immune mechanism  
10         13 096       2.3 8           14 711       2.5 8        15 349       2.5 
Other natural causes            248 519     43.4            252 480     42.4         255 434     42.3 
Non-natural causes              49 456       8.6              53 300       9.0           54 455       9.0 
 
All causes 
 
           572 673      100 
     
           595 152      100 
    
        604 100      100 
Reference: Statistical release P0309.3 Mortality and causes of death in South Africa, 
2009: Findings from death notification. (11) 
 
1.2.2 Definition 
 
The term CKD is an all-encompassing one. It refers to a heterogeneous group of 
conditions affecting both the structure and function of the kidney. The definition 
refers to either, the presence of structural damage to the kidney or a glomerular 
filtration rate (GFR) of less than 60ml/min/1.73m2, which is indicative of decreased 
4 
 
 
renal function, for a period of three months or more (12). The rationale for selecting 
these cut-off values is that reduction in kidney function to a level of 60ml/min/1.73m2 
or lower represents loss of half or more of the adult level of normal kidney function 
(13). Based on GFR estimation, the National Kidney Foundation has classified CKD 
into five stages- see Table 2. 
Table 2: Stages of chronic kidney disease 
 
ESRD, end-stage renal disease; GFR, glomerular filtration rate. 
Adapted from the National Kidney Foundation: KDOQI Clinical practice guidelines for 
chronic kidney disease: Evaluation, classification, and stratification. Am J Kid 
Disease 2002;39:S1-S266 (14) (reprinted with permission) 
 
Classification of CKD into the above stages of 1 to 5 facilitates patient care, as it 
allows for the application of stage-specific clinical management plans and allows for 
better communication between the relevant health care providers (14). The rate of 
progression to kidney failure depends on the primary diagnosis and the timeous 
implementation of secondary preventive measures. Although the majority of people 
with early stages of CKD do not progress to ESRD, stages 4 and 5 are of particular 
importance. Stage 4 is when plans for chronic renal replacement therapy (RRT) 
Stage Description GFR (mL/min/1.73 m2)  
1 Kidney damage with normal or elevated GFR ≥90 
2 Kidney damage with mildly decreased GFR 60-89 
3 Moderately decreased GFR 30-59 
4 Significantly decreased GFR 15-29 
5 Kidney failure (ESRD) <15  
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should be formulated and stage 5 is the point that RRT is instituted. Well-timed 
initiation of RRT is vital to prevent the complications of uraemia that ultimately 
contribute to significant morbidity and mortality. 
1.2.3 Renal Replacement Therapy  
Renal replacement therapy (RRT) involves either dialysis or a kidney transplant. In 
South Africa dialysis is the mainstay of treatment of the majority of these patients, as 
the transplant rate is relatively low at 9.2 per million population (8). The limited 
availability of both living and cadaveric donor organs is a problem. The lack of 
access to RRT in developing countries  is highlighted by the fact that only a tiny 
proportion of the more than 1.7 million patients worldwide with CKD that access 
renal replacement therapy reside in sub-Saharan Africa (5, 15).  In comparison to 
many African countries, dialysis in South Africa is available in both the private and 
public sector. However, on account of the limited resources in the public sector, 
specific criteria are used to select eligible candidates for RRT; these patients need to 
be eligible for a kidney transplant (8). 
Dialysis is instituted with the aim of mimicking the excretory function of the kidneys. 
There are two forms of dialysis available, haemodialysis and peritoneal dialysis. 
Decisions to institute haemodialysis instead of peritoneal dialysis, and vice versa, 
are based on a myriad of factors such as patient preference, physician bias, co-
morbidities, occupation, time constraints, living circumstances, costs and availability 
of the equipment and staff necessary for each of these modalities (16). Both 
methods of dialysis have advantages and disadvantages associated with them (17). 
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Haemodialysis (HD) is the commonest modality of RRT used in patients with ESRD. 
It is usually required at least three times per week, with each session lasting 
approximately 4 hours.  Access to the patient's blood is obtained via an arterio-
venous fistula or graft, or via a temporary or permanent central venous catheter. The 
principal benefit of this form of dialysis is the capacity to rapidly eliminate substances 
and excess fluid volume. Disadvantages include more severe anaemia due to blood 
loss from clotting of blood lines and dialyzers or excess bleeding (from burst 
dialyzers, over-heparinazation),  haemolysis associated with contamination of 
dialysate water or membrane incompatibility as well as loss of water-soluble vitamins  
such as folate and vitamin B12 through haemodialysis membranes. The life span of 
red cells is shortened by approximately 30% in those receiving haemodialysis 
(18).  Infection is an important cause of mortality and morbidity among these 
patients, especially in the case of  those using a central venous catheter for HD 
access (16). 
In peritoneal dialysis (PD), the peritoneal membrane acts as the endogenous 
semipermeable membrane across which dialysis occurs. Since the early 1980s, PD 
has been increasingly utilized as a dialysis option worldwide (17). Peritoneal dialysis 
patients appear to be more satisfied with their therapy than those on HD (17, 19). 
Peritoneal dialysis is associated with lower rates and lesser degrees of anaemia 
compared to haemodialysis. The reasons for the lower rates of anaemia include the 
better conservation of the remaining renal function in patients on peritoneal dialysis 
and being exempt from the above described reasons for blood loss and reduced red 
cell survival that patients on HD are subject to (18, 20). 
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1.3 Anaemia and Renal Failure 
1.3.1 History  
The first proper description of anaemia related to renal failure can be attributed to 
Robert Christison. He noted in his 1839 publication: “by far the most remarkable 
character of the blood in the advanced stage of Bright’s disease is a gradual and 
rapid reduction of its colouring matter or haematosin” (21, 22).  In spite of these and 
other observations, anaemia in renal disease was only mentioned in passing until the 
early 1900’s.  
1.3.2 Definition and diagnosis 
Normal haemoglobin (Hb) distributions vary with age, sex and physiological status. 
Anaemia is defined as the absolute reduction of the circulating red cell mass. This is 
reflected by a reduced haemoglobin, haematocrit or red cell count. The World Health 
Organization (WHO) definition of anaemia states that anaemia is present when the 
Hb concentration is <13.0 g/dl in males and <12.0 g/dl in females (23).  Anaemia is a 
common complication of CKD. It develops early in the progression of chronic kidney 
disease and is worsened with the deterioration of renal function. Although there are 
effective treatment options, the condition is often under-treated (24). In the third 
National Health and Nutrition Examination Survey (NHANES) the prevalence of 
anaemia in stage 3 CKD was 5.2%, increasing to 44.1% in stage 4, and involving 
majority of the patients in stage 5 CKD (25). Studies report that the prevalence of 
anaemia increases from 1% in patients with a GFR of 60 ml/min/1.73 m2 to 9% at a 
GFR of 30 ml/min/1.73 m2 and ultimately to 33% for men and 67% for women at 
stage 5 CKD or ESRD (14, 26).  
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(27) (reprinted with 
permission, see Appendix C) 
Figure 1: Anaemia prevalence and CKD stage   
 
1.3.3 Pathogenesis 
The pathogenetic mechanisms of anaemia in CKD are multifactorial. There is a 
complex interaction between neurohormonal and inflammatory responses, iron 
deficiency and impaired iron mobilization, blood loss, haemodilution and the effects 
of medication that leads to subnormal haemoglobin (7, 18, 28, 29). 
9 
 
 
 
Figure 2: Pathogenesis of Anaemia in CKD 
References : Agarwal AK. J A Med Dir Assos 2006;7:s7-s12 (30)                                     
Kalra PA. Br J Cardiol 2011;18(Suppl 2):s1-s15 (31)                                               
(reprinted with permission, see Appendix C) 
 
1.3.3.1 Reduced red cell survival 
 
 The average red blood cell survives about 120 days, with a daily turnover of 
approximately 1% of the total red cell pool. To maintain a stable Hb level, 
approximately 200 billion new red blood cells must be created daily (18). However, in 
ESRD, red cell survival is shortened, with the lifespan in patients on haemodialysis 
reduced by up to 33% (28). The basis is that the reduced red blood cell lifespan in 
renal disease is primarily due to the toxic uraemic setting with contributions from 
ongoing infection, mechanical damage during HD and the accumulation of advanced 
glycation end products  on the red cell membrane in diabetes mellitus (32, 33). The 
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decline in haemoglobin concentration may begin at a creatinine clearance of around 
70 ml/min among men and 50 ml/min among women (34).   
1.3.3.2 Blood loss 
Patients with CKD are at increased risk of blood loss. Reasons include development 
of an associated gastritis resulting in upper gastrointestinal blood loss and uraemia- 
induced platelet dysfunction (35). Chronic blood loss resulting from recurrent 
phlebotomy for laboratory investigations and loss of blood in the dialysis circuit and 
dialyzer during each haemodialysis session may also contribute to deteriorating Hb 
levels. Iron losses are 10-20 times greater than normal in haemodialysis patients 
(36). 
1.3.3.3 Iron deficiency 
Iron homeostasis is deranged in CKD. Transferrin, a carrier protein responsible for 
transporting both absorbed and stored iron necessary for erythropoiesis is 
decreased, thereby limiting iron carrying capacity. This is further compounded by the 
limited ability to mobilize iron from macrophages and the liver. Typical iron studies in 
a patient with advanced CKD (i.e. stages 4 and 5) demonstrates a decreased level of 
transferrin and an elevated ferritin representing an inter-organ functional blockade 
that creates a rate limiting step in erythropoiesis (28). 
1.3.3.4 Erythropoietin deficiency 
In CKD there is a primary deficiency of erythropoietin (EPO) (28). This hormone is 
produced by the peritubular interstitial cells within the kidney. These cells, located at 
the tips of the renal pyramids, are sensitive to hypoxia (32). Hypoxia in an individual 
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with normally functioning kidneys leads to erythropoietin gene transcription. The 
increased EPO hormone levels stimulate the bone marrow by accelerating the rate 
and number of colony-forming units (CFU-E) undergoing differentiation into red blood 
cells and, hence increasing erythropoiesis. However in  chronic kidney disease, 
there is primary paucity of erythropoietin production by the interstitial fibroblasts , 
thereby leading to anaemia (37). The kidney produces approximately 90% of 
circulating erythropoietin in the body, therefore the level of anaemia that develops is 
directly related to the amount of residual renal function present  (38).  
 
 
Figure 3:  Erythropoietin and feedback regulation of erythropoiesis 
Reference: Jelkmann W. The Journal of Physiology 
Volume 589, Issue 6, pages 1251-1258 (39)    (reprinted with permission, see 
Appendix C) 
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1.3.3.5 Blockade of renin angiotensin system 
The renin angiotensin system (RAS) impacts on the production of erythropoietin. 
Angiotensin causes efferent artery vasoconstriction thus increasing the filtered load 
of sodium. Increased filtered sodium increases oxygen consumption thus 
contributing to the development of a relative hypoxia in the region of the peritubular 
cells. This leads to an increase in EPO production. Blockade of the RAS prevents 
the above from occurring (32). 
 Angiotensin converting enzyme (ACE) is responsible for actions against many 
substrates. It has two homologous N- and C-terminal active domains (40, 41). N-
acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP) is one of the substrates that are 
hydrolyzed by the N-terminal active site of ACE (42). Ac-SDKP reversibly prevents 
the maturation  of pluripotent hematopoietic stem cells and early progenitors by 
preventing the progression of these cells into S phase of the cellular cycle by 
maintaining them in G0 phase (43). The link between Ac-SDKP and the prevention 
of proliferation of erythroid progenitor cells suggests an inhibitory role of Ac-SDKP on 
haematopoiesis. The chronic administration of the angiotensin-converting enzyme 
(ACE) inhibitor thus increases the plasma levels of this natural stem-cell regulator, 
thereby impacting negatively on erythropoiesis (44). 
1.3.3.6 Inflammation 
A study by Cheung et al (2010) stated that some of the causes of an increase in 
serum levels of pro-inflammatory cytokines may be due to various factors ranging 
from reduced renal function and volume overloaded states to increased oxidative 
stress and an increased susceptibility to infection in uraemia (45). 
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Consequences of persistent inflammatory activity have extensive implications in 
patients with CKD. High C-reactive protein levels (used as a surrogate marker of 
inflammatory activity) are a predictor of more erratic haemoglobin control in patients 
with CKD (29). One study demonstrated that even in the absence of infection and 
other causes of inflammation, patients on chronic maintenance dialysis had CRP 
levels persistently between 5-50mg/dl (46). Mueller et al. conducted a study over 6 
months in more than 1500 haemodialysis patients to determine patterns of Hb 
variability and the possible causative factors (47). The study demonstrated that lower 
CRP values were associated with better Hb control (p < 0.0001), with no significant 
differences in other parameters such as ferritin or transferrin saturation. The authors 
concluded that the difference in the CRP (presence of inflammation) played an 
important role in haemoglobin variability (47).  Increased levels of pro-inflammatory 
cytokines (tumour necrosis factor and interleukin 6) in chronic kidney disease 
adversely impact on bone marrow erythropoiesis, reduce erythropoietin production 
and affect iron metabolism leading to hypo-responsiveness to ESAs and suboptimal 
treatment response (48-50). 
Inflammation also serves to upregulate hepcidin production by the liver. Hepcidin  
inhibits iron absorption from the gastrointestinal tract and reduces iron release from 
reticuloendothelial macrophages, thus contributing to an anaemia of chronic disease 
(28). 
1.3.3.7 Hyperparathyroidism 
Secondary hyperparathyroidism present in advanced renal disease develops as a 
result of decreased active vitamin D production by the kidneys as well as phosphate 
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retention, leading to the development of hyperphosphataemia, hypocalcaemia, and 
increased parathyroid hormone (PTH) levels.  Parathyroid hormone oversecretion 
adversely impacts erythropoiesis. Consequences include erythropoietin 
hyporesponsiveness, suppression of erythropoiesis and shortened red cell survival 
by induction of haemolysis. Bone marrow fibrosis is also a documented result of 
hyperparathyroidism (51-53). The last phase of the Dialysis Outcomes and Practice 
Patterns Study identified hyperphosphataemia, hypocalcaemia, and high PTH as 
three independent risk factors for all-cause and cardiovascular mortality (54). 
1.3.4 Impact of Anaemia 
Anaemia in patients with CKD is associated with a wide variety of complications. 
These range from symptoms such as lethargy, dizziness, and dyspnoea to more 
disabling and ominous effects on the cardiovascular system, including left ventricular 
hypertrophy and congestive cardiac failure (55); as well as deterioration in cognition, 
mental acuity and exercise tolerance, all negatively impacting on quality of life (56, 
57). The Dialysis Outcomes Practice Pattern Study (DOPPS), conducted in twelve 
countries, demonstrated that haemoglobin concentrations less than 11g/dl in patients 
with CKD were associated with an increase in hospitalization and mortality (57). 
Haemoglobin levels that are either too high or too low may have an adverse effect on 
patient outcomes (29). In type 2 diabetic patients, even mild anaemia has been 
demonstrated to be an independent risk factor associated with the progressive 
decline of kidney function to ESRD (58). The hypoxia secondary to the anaemia 
stimulates the renin-angiotensin-aldosterone system, thus leading to renal 
vasoconstriction and worsening renal function. 
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Anaemia is a significant problem in patients with CKD. Prompt and accurate 
diagnosis is required in order to avoid serious consequences. The advantages of 
treatment of the anaemia associated with renal disease extend to  improvement in 
physical mobility, exercise capacity and endurance, as well as factors that determine 
patient satisfaction such as sexual function, cognition, psychological wellbeing and 
social interaction (56, 59). 
1.3.5 Treatment 
Optimal treatment of anaemia in patients with CKD involves addressing any 
contributing cause, the use of recombinant human erythropoietin and intravenous 
iron. Adequate iron stores as well as exogenous erythropoietin administration are 
generally required to produce an appropriate increase in haemoglobin in patients 
with CKD. Poor response to treatment with EPO and iron may be due to several 
factors including the presence of iron deficiency, ongoing blood losses, inflammation, 
EPO resistance, drug use and haemoglobinopathy (30, 60). Other causes of 
anaemia that are not related to erythropoietin deficiency should be looked for, using 
both clinical assessment and appropriate investigations. Anaemia is one of the 
easier complications of CKD to diagnose and treat (61).  
1.3.5.1 Erythropoietin Stimulating Agents 
Until approximately 20 years ago, the basis of treatment of anaemia in ESRD was 
blood transfusion. This was accompanied by a significant risk of infectious and non-
infectious complications. Subsequently the management of anaemia secondary to 
renal disease has been enhanced by the introduction of recombinant human 
erythropoietin, also known as erythropoietin stimulating agents (ESA’s) (57). The first 
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recombinant human erythropoietin (Epogen® [epoetin alfa]), introduced in 1989, 
significantly impacted on the management of anaemia of CKD in dialysis patients. 
Approximately 15 years later, in 2005, 99% of in hospital haemodialysis patients in 
the United States of America received ESA treatment (62). 
Recombinant human EPO has a variety of glycosylation patterns giving rise to the 
different forms- alpha, beta, delta, and omega. These products differ in half life, 
pharmacokinetics and affinity for the receptor (63). The table below demonstrates 
the different types of ESAs – some are not yet available. 
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Table 3: Types of Erythropoietin, Half Life, Administration Route and Frequency 
ESA CLASS ESA TYPE ½ LIFE (hours) ADMINISTRATION 
ROUTE 
PERIODICITY 
Unmodified 
Recombinant 
EPOs 
‘short acting’ 
Epoetin alpha 8.8 / i.v. 
24.2 / s.c. 
IV or SC 1-3 times/wk. 
 Epoetin beta 6.8 / i.v. 
19.4 / s.c. 
 1-3 times/wk. 
 Epoetin omega    
 Epoeitin delta    
Long-- 
Acting 
ESAs 
Darb-- 
Epoetin 
alpha 
25 / i.v.  
49 / s.c 
IV or SC Every 1-2 wks. 
 C.E.R.A 133 / i.v. 
137 / s.c. 
IV or SC Every 2-4 wks. 
EPO 
analogues 
(Biosimilar 
 EPOs) 
Epoetin alfa   1-3 
times/wk. 
(64) Epoetin zeta 4-5 / i.v. 
24 / s.c. 
IV or SC 1-3 
times/wk. 
Investigational 
ESA 
 Synthetic, 
peptide  
based 
erythropoietin  
receptor  agonists 
14-60 / p.o PO Every 
4 wks. 
ESA-erythropoiesis stimulating agents; Rhu- recombinant human erythropoietin; EPO- erythropoietin; 
C.E.R.A- Continuous erythropoietin receptor activator; I.V.- intravenous; S.C.- subcutaneous; P.O- 
per os 
Adapted from Locatelli F,and Del Vecchio L.The Oncologist 2011;16:19-24 (65), 
Foley, R. N. Emerging erythropoiesis-stimulating agents. Nat.Rev.Nephrol. 
2010;6:218-223 (66) 
 
EPO Resistance 
Studies have demonstrated that EPO levels are approximately five times higher in 
patients with CKD as compared to those without CKD, but are inappropriately low for 
the degree of anaemia present (67).  This demonstrates that in addition to the 
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relative EPO deficiency present, resistance to the stimulating effect of EPO on the 
bone marrow erythropoeisis is also present. 
1.3.5.2 Iron 
Without sufficient iron stores ESAs will not be effective, it is therefore often 
necessary to use iron therapy to achieve target-range haemoglobin. Furthermore, as 
an adjuvant it  may serve to minimize the dose of ESA needed to achieve the target 
haemoglobin (14).  The KDOQI Clinical Practice Guidelines and Clinical Practice 
Recommendations for Anaemia in Chronic Kidney Disease defines iron deficiency as 
“a serum ferritin concentration < 100 ng/ml in non–dialysis-dependent CKD and in 
patients treated by PD and a serum ferritin concentration of < 200 ng/ml in 
haemodialysis patients.” (68)  A transferrin saturation of < 20% indicates iron 
deficiency in all patients with CKD, regardless of whether they are receiving dialysis 
or not (68). The content of haemoglobin in reticulocytes (CHr) is the more accurate 
method of measuring iron status, however this assay is not readily available (14). 
Iron deficiency may be corrected by the oral and intravenous routes; intravenous 
therapy results in more rapid correction, while oral iron therapy takes several 
months. If iron supplementation is required the benefits of iron therapy, namely 
anaemia amelioration and the benefits thereof, minimization of blood transfusion 
requirements and optimization of ESA therapy must be weighed against the risks 
and side effects. Risks include gastrointestinal side effects with oral form of therapy 
and rarely, anaphylactoid reactions with intravenous therapy and other acute effects 
(hypotension, rigors, muscular pain, nausea, dyspnoea, wheezing, stridor, chest 
pain, facial flushing, rashes, and symptoms of porphyria-cutaneous) (12, 69). Three 
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intravenous iron products are available, iron dextran, sodium ferric gluconate, and 
iron sucrose.  
The KDIGO guidelines, released in 2012, recommend that intravenous iron be 
routinely used in patients on haemodialysis and peritoneal dialysis, as it is doubtful 
that these patients will absorb an adequate amount  if administered as an enteral 
preparation (68). In patients not on RRT, the decision of oral versus IV therapy must 
be based on the severity of iron deficiency, cost, ease and complications of venous 
access, side effect profile and response to previous iron treatment. Ongoing iron 
therapy is determined by the response to therapy in terms of haemoglobin, side 
effects, iron studies and ESA usage. 
1.3.6 Treatment targets 
 
Analysis of the United States Renal Data System demonstrated that the average 
levels of haemoglobin increased from 10g/dl in 1993 to 12g/dl in 2005, with a 
doubling of the ESA doses used (70). 
Pivotal studies include the Correction of Haemoglobin and Outcomes in Renal 
Insufficiency (CHOIR) study (71), Cardiovascular Risk Reduction by Early Anaemia 
Treatment With Epoetin Beta (CREATE) study (38) and the most recent, The Trial to 
Reduce Cardiovascular Events With Aranesp Therapy (TREAT) study (72). 
In the CHOIR study, Singh et al (71) randomized patients with pre dialysis CKD. 
Patients were to receive recombinant erythropoietin alpha to achieve a target Hb 
concentration of 13.5 g/dl in one arm versus a target Hb concentration of 11.3 g/dl in 
the other. The investigators hypothesized that there would be a lower rate of 
20 
 
 
complications from cardiovascular causes and death in patients with a higher Hb 
level. However, it was demonstrated in this study that patients in the arm randomized 
to achieve the higher Hb concentration had an increased risk of cardiovascular 
complications (myocardial infarction, hospitalization for congestive heart failure, 
hypertension and stroke) and death.  
The primary objectives of the open, randomized, multicentre CREATE trial 
conducted in Europe, Mexico and Asia were to investigate the effects of early 
anaemia correction on the development of left ventricular hypertrophy and the time 
to first cardiovascular event. The conclusion was that in patients with CKD, 
correction of anaemia using erythropoietin to a target haemoglobin range of 13–15 
g/dl did not reduce the risk of cardiovascular events or all-cause mortality (73). 
The TREAT trial was conducted to evaluate treatment of anaemia with darbepoetin 
alfa and the subsequent effects on progression of renal disease, cardiovascular 
disease (myocardial infarction, unstable angina, heart failure, and stroke) and 
mortality in patients with CKD and type 2 diabetes. The patients randomized to the 
treatment arm had a target Hb of 13g/dl. There was no significant difference between 
the patients randomized to receive darbopoetin alpha versus placebo with respect to 
myocardial events; however higher risk of venous and arterial thromboembolic 
events, stroke, and hypertension with the use of darbepoetin alfa was 
demonstrated (72). 
As a result of these trials, the U.S. Food and Drug Administration added a black-box 
warning to the labelling of epoetin alfa and darbepoetin alfa stating that “ESAs 
should be used to maintain haemoglobin levels between 10 g/dl to 12 g/dl. 
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Maintaining higher haemoglobin levels in patients with chronic kidney failure 
increases the risk for death and for serious cardiovascular reactions such as stroke, 
heart attack, or heart failure.” (74). 
All of these trials have led to the KDIGO Clinical Practice Guideline for Anaemia in 
Chronic Kidney Disease released in 2012 stating that the present suggestion is not 
to exceed in general a Hb limit of 11.5 g/dl (as the upper limit in the pivotal studies 
does not exceed 11.5g/dl) (68).  
1.3.7 Guidelines and Changing Targets 
 
Guidelines have been developed in order to assist doctors in making judicious 
decisions based on the strongest possible evidence. The table below demonstrates 
how guidelines have changed over the years based on research regarding the use of 
ESAs and the risks thereof. 
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Table 4: Changing targets of haemoglobin, ferritin and ESA use 
Year Guideline Recommended Hb 
target (g/dl) 
Recommended 
ferritin target (mcg/l) 
1997 NKF DOQI Clinical Practice Guideline 
for Anaemia of Chronic Renal Failure 
11-12 200-400 
1999 European Best Practice Guidelines for 
the Management of Anaemia in 
Patients with Chronic Renal Failure a  
11-no upper limit 200-500 
2001 NKF-K/DOQI Clinical Practice 
Guidelines for Anaemia of Chronic 
Kidney Disease: Update 2000 
b
 
11-12 ≥100 
2004 Revised European best practice 
guidelines for the management of 
anaemia in patients with chronic renal 
failure 
c
 
≥11  
2007 KDOQI Clinical Practice Guideline and 
Clinical Practice Recommendations for 
Anaemia in Chronic Kidney Disease: 
2007 Update of Haemoglobin Target 
11-12 
Not to exceed 13 if 
receiving ESA 
therapy 
Iron therapy not 
recommended if 
ferritin ˃500-800 
2012 KDIGO 2012 Clinical Practice Guideline 
for the Evaluation and Management 
of Chronic Kidney Disease 
ESAs not to be used 
to maintain Hb 
concentration above 
11.5 g/dl.  
11-12 in the 
paediatric 
population 
 
 
References: a - Cameron J.S. European best practice guidelines for the management of 
anaemia in patients with chronic renal failure. Nephrol Dial Transplant. 1999;14 Suppl 2:61-
5.(75) 
b -  NKF-K/DOQI Clinical Practice Guidelines for Anaemia of Chronic Kidney Disease: 
update 2000. Am J Kidney Dis 2001 Aug;38(2):442.(13)  
c - Locatelli, F. et al. Revised European best practice guidelines for the management of 
anaemia in patients with chronic renal failure. Nephrol Dial Transplant. 2004 May;19 Suppl 
2:ii1-47.(76) 
 
Currently national and international guidelines are being utilized in nephrology units 
around South Africa, including Chris Hani Baragwanath Academic Hospital. 
However, it is not documented as to how strictly these guidelines are adhered to, 
23 
 
 
and if not, the reasons thereof. No studies done at this centre have compared 
haemoglobin levels, iron supplementation and erythropoietin doses in haemodialysis 
and peritoneal dialysis populations. Therefore it is the aim of this study to perform a 
retrospective cross sectional audit and comparison of haemoglobin levels, and the 
possible causes of anaemia and management thereof, among the haemodialysis 
and peritoneal dialysis populations at Chris Hani Baragwanath Academic Hospital 
dialysis unit. The  anaemic (haemoglobin <10g/dl) and non-anaemic groups were 
also compared  in terms of demographic data, cause of ESRD, duration on dialysis, 
blood loss, sepsis, hyperparathyroidism and use of concomitant medication. 
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CHAPTER 2: METHODS 
2.1 Study Design 
 
A single centre retrospective cross sectional audit and comparison of haemoglobin 
levels, and the possible determinants and  management thereof, among the 
haemodialysis and peritoneal dialysis patient  populations  that were on the chronic 
dialysis programme at the Nephrology Unit of Chris Hani Baragwanath Academic 
hospital during the month of  January 2012. 
Patients’ records, using both paper-based records and electronic records in the form 
of Bara Active Renal Tracking (BART) programme were analyzed, as monthly blood 
results and reviews by doctors are recorded in either one, or both, of these forms of 
patient records. 
Data collection occurred in January 2012, as this was when a comprehensive set of 
relevant laboratory investigations were checked in the chronic dialysis population in 
the Unit as per the unit protocol, that required comprehensive testing every 6 
months. 
2.1.2 Inclusion criteria  
 
 The inclusion criteria included 
- all patients on the chronic dialysis programme at CHBAH during January 2012 
(except those that were HIV positive). 
- all patients on the chronic dialysis programme for longer than three months 
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2.1.2 Exclusion criteria 
 
The exclusion criteria included 
 - HIV positive patients on the chronic dialysis programme at CHBAH 
- all patients who were on the chronic dialysis programme for less than three 
months 
HIV positive patients were excluded from the study as there were too many factors 
unrelated to their renal condition that may have contributed to anaemia in these 
patients. 
Permission to conduct the study was obtained from the Department of Nephrology 
and hospital management at Chris Hani Baragwanath Academic Hospital. 
2.2 Ethics and confidentiality 
 
The University of the Witwatersrand Ethics committee granted ethics approval 
unconditionally in May 2012 (clearance certificate M120513). 
Anonymity of the patient was maintained throughout the data collection process as 
no names were recorded. Every patient was allocated a study number/ identifier 
code which was recorded on the data collection sheet. Information regarding the 
corresponding names to the study numbers is only accessible to me, the primary 
investigator. 
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2.3 Data collection and Analysis 
 
The data collected, included the following: 
- Age 
- Race 
- Sex 
- Form of Dialysis 
- Duration of dialysis 
- Compliance on dialysis 
- Cause of CKD if known 
- HIV status 
- Haemoglobin 
- Haematocrit 
- Iron studies 
- Calcium 
- Phosphate 
- Parathyroid Hormone 
- Albumin 
- C-reactive protein 
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- Red cell Folate 
- Vitamin B12 
- Medications- the use of Angiotensin converting enzyme inhibitors/Angiotensin 
receptor blocker 
- Transfusions of packed red cells in the preceding six months and number of 
units 
- Presence of sepsis, malignancy or blood loss  
- The use of recombinant erythropoietin (Recormon®- erythropoietin beta) and 
the dose and route of administration 
- The use of intravenous iron (Venofer®-iron sucrose) and the dose 
 
Hypertension and diabetes were defined in accordance with the parameters stated in 
the South African Hypertension Guidelines 2011 and the SEMDSA Diabetic 
Guidelines 2012.  
With reference to HD, dialysers were not reused and reverse osmosis unit were not 
utilized. 
Data was collected electronically using the REDCap (Research Electronic Data 
Capture) tool. This tool was obtained through the University of Witwatersrand and 
training was providing regarding use of this tool. Internet access is required to 
access this databank and is available through any internet enabled device. The 
databank is protected by means of username and password access. The data 
28 
 
 
collection sheet was personally designed to capture all the required information and 
was updated on the internet after every patient entry.  See Appendix B for data 
collection sheet. 
The data was verified using tools available on the REDCap data collection tool and 
then exported to Microsoft Excel. All descriptive data were analyzed using means 
and standard deviations for the parametric data and medians and confidence 
intervals for the non-parametric data. Categorical data are described using 
frequencies and percentages. These were obtained from the Excel spreadsheet. 
Graphs such as pie charts and frequency distribution tables were compiled using 
Microsoft Excel. 
Contingency tables were drawn up from the Excel spreadsheet. The GraphPad 
InStat programme was utilized to further analyze the data in remaining outcomes 
that needed to be assessed. The chronic haemodialysis and the chronic peritoneal 
dialysis populations, as well the anaemic and non-anaemic groups, were compared  
using a Chi-square test which was used for comparisons between groups with 
categorical variables and the unpaired t test was used to compare groups with 
normally distributed variables. To compare proportions between the two groups, a 
Fisher’s exact test was performed. A p-value of < 0.05 was taken as significant. 
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CHAPTER 3: RESULTS 
3.1 The chronic dialysis population 
3.1.1 Demographics of the chronic dialysis population 
The audit included all patients that were on the chronic dialysis programme at the 
Chris Hani Baragwanath Academic Hospital during the month of January 2012. A 
total of 140 patients were reviewed but only 136 were analysed. The remaining 4 
patients were excluded based on the exclusion criteria, as 2 patients were HIV 
positive and 2 patients had been on the chronic programme for less than three 
months. 
Table 5: Demographics of patients that underwent chronic dialysis in January 2012 (n=136) 
 
 
 
 
 
 
The demographics of all 136 chronic dialysis patients are represented in Table 5. 
The mean age was 45 ± 13 years, 77 patients (56.6%) were male. The cohort was 
comprised of 118 patients, (87%) of Black race, followed by Whites (5%), Coloureds 
(5%) and Indians (3%) as depicted in Figure 4. In the case of one of the patients the 
race was not stated. 
Age  (in years)  45±13 
Gender Male 77 (56.6%) 
n (%)        Female 58 (42.6%) 
               Not stated 1 (0.8%) 
Race   Black 118 (87%) 
n (%) White 7 (5%) 
            Indian 3 (2%) 
            Coloured 7 (5%) 
            Not stated 1 (1%) 
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The mean duration on dialysis for the population was 37.7 ± 28.6 months. 
 
Figure 4: Race of patients on chronic dialysis 
 
 
Figure 5: Gender of patients on chronic dialysis 
 
3.1.2 Causes of Chronic Kidney Disease 
 
The causes of chronic kidney disease in the entire chronic dialysis population are 
demonstrated in figure 6. In the vast majority of patients, 89 out of a possible 136 
patients (65%), the cause of kidney disease is unknown. The remaining three most 
common causes included hypertension(17%), diabetes mellitus(5%) and primary 
glomerulonephritis(5%). 
87% 
5% 2% 5% 
1% 
Race (n=136) 
Black White Indian Coloured Not stated
56% 
43% 
1% 
Gender (n=136) 
Male Female Not stated
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Figure 6: Causes of chronic kidney disease 
 
3.2 Comparison of the chronic haemodialysis and the chronic peritoneal 
dialysis populations 
3.2.1 Demographics 
 
In January 2012, 136 patients were undergoing chronic dialysis. 77 were on 
haemodialysis (56%) and 59 were on chronic peritoneal dialysis (44%). The following 
tables depict the race, gender and age distributions within the two populations 
respectively. 
Table 6: Race distribution in HD and PD populations 
 HD (n=77) PD (n=59) 
Black 68(88%) 50(85%) 
White 5(6.5%) 2(3%) 
Indian 0 3(5%) 
Coloured 3(4%) 4(7%) 
Not stated 1(1.5%) 0 
0 20 40 60 80 100
Reflux nephropathy
Previous nephrectomy
Primary Oxaluria
Secondary Glomerulonephritis
Adult Polycystic Kidney Disease
Chronic Interstitial Nephritis
Diabetes Mellitus
Primary Glomerulonephritis
Hypertension
Unknown
0.7 % 
0.7% 
0.7% 
2.2% 
2.2% 
2.2% 
5.9% 
5.9% 
17% 
65.4% 
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Table 7: Gender distribution in HD and PD populations 
 HD(n=77) PD(n=59) 
Male 43 34 
Female 34 24 
Not stated  0 1 
 
Table 8: Average age and standard deviation in HD and PD populations 
 HD(n=77) PD(n=59) 
Average Age (years) 44.77±14.19 47.47±11.71 
 
On average, patients in the HD group were on the chronic dialysis programme longer 
than those in the PD group (43 ± 32 months versus 31 ± 21 months; p = 0.0137). 
3.2.2 Causes of Chronic Kidney Disease  
 
As is demonstrated in figure 7, in both cohorts of patients, the cause of CKD was 
unknown in majority of the patients - 72% in the haemodialysis group and 56% in the 
peritoneal dialysis group. In the haemodialysis group, the other causes included 
adult polycystic kidney disease (1.3%), reflux nephropathy (1.3%), previous 
nephrectomy (1.3%), primary oxaluria (1.3%), chronic interstitial nephritis (1.3%), 
secondary glomerulonephritis (4%), diabetes mellitus (5%), hypertension (6.5%) and 
primary glomerulonephritis (6%). In the peritoneal dialysis populations the known 
causes included primary glomerulonephritis (3.3%), adult polycystic kidney disease 
(3.3%), reflux nephropathy (3.3%), diabetes mellitus (12%) and hypertension (32%). 
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Figure 7: Table comparing causes of CKD in the peritoneal dialysis and haemodialysis groups  
 
3.2.3 Vascular access in the haemodialysis cohort 
 
 
Figure 8: Types of vascular access in haemodialysis groups  
 
Less than half of the patients (37 i.e. 48%) that were being dialysed on the chronic 
dialysis programme at the time of the study were being dialysed via an arteriovenous 
fistula. The rest of the patients had vascular access in the form of temporary venous 
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catheters (22%) or a cuffed catheter for permanent venous access (13%). In 13 
patients (17%) the means of vascular access was not stated in either electronic or 
paper based database. 
3.2.4 Anaemia  
In order to assess the status of anaemia correction in the haemodialysis versus 
peritoneal dialysis groups, levels of haemoglobin and the haematocrit were 
analysed. As is demonstrated below, the average Hb level within the peritoneal 
dialysis group was significantly higher as compared to the average within the 
haemodialysis group (11.3±2.3g/dl versus 10.1±2.6g/dl; p ˂ 0.001). In keeping with 
the Hb result, the average haematocrit was also higher within the PD population 
(0.31 ± 0.08L/L) as compared to the HD population (0.35 ± 0.09L/L) (p = 0.0144).  
 
Figure 9: Comparison of average haemoglobin  
 
As per the definition of iron deficiency with regards to ferritin levels set out in the 
KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for 
Anaemia in Chronic Kidney Disease, 11 HD (14%)  and 10 PD patients (17%) were 
iron deficient. The median ferritin levels were higher in the HD group  than the PD 
group [519μg/L (IQR 264-838) versus 232μg/L (IQR 127-438)];(p ˂ 0.0001). 
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3.2.4.1 Management of anaemia  
 
In terms of management of anaemia, the use of erythropoiesis stimulating 
agents/erythropoietin, the use of intravenous iron and transfusion of packed red cells 
were reviewed.   
94% of the haemodialysis cohort as compared to 74% of the peritoneal dialysis 
cohort was receiving ESAs as part of their monthly prescription at the time of data 
collection. The doses prescribed of the ESA were also significantly higher among the 
HD group (68 055 ± 43718 u/month versus 27720 ± 26157 u/month; p˂0.001). Both 
groups received the ESAs via the subcutaneous route. 
An attempt was made to assess the compliance with the doses of ESAs prescribed 
in the PD population by assigning patients to one of the following categories- 
optimal, suboptimal or not stated. Unfortunately 67% of the peritoneal dialysis 
patients fell within the ‘not stated’ group, thus limiting the value of the results of this 
aspect of data analysis. Compliance with ESAs is not a concern in patients on HD as 
the ESA is administered by the nursing staff in the dialysis unit at the time of the 
dialysis session. 
According to the databases the majority of the HD and PD patients were not 
receiving intravenous iron therapy. 31 HD patients (40%) and 9 PD patients (16%) 
received IV iron as part of their prescription in the month under review. The 
difference in average monthly doses within the 2 groups was not statistically 
significant. 
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Only two patients received transfusions of packed red cells in the preceding six 
months to the period under review, both of whom were undergoing haemodialysis. 
One patient received 2 units and the other 4 units. The likely precipitant for the 
requirement of the transfusion in the first case was the presence of pure red cell 
aplasia and in the second case the presence of severe sepsis. 
 
3.2.4.2 Contributors to anaemia 
 
The comparison of the means/medians of the biochemical parameters that were 
considered are tabulated below in table 9. The comparisons between HD and PD 
that yielded statistically significant results were that of phosphate, parathyroid 
hormone and albumin levels.   
Table 9: Biochemical parameters possibly contributing to anaemia 
 HD PD p value 
Corrected calcium-mmol/L 
(mean and std dev.) 
2.24±0.21 2.27±0.21 0.2033 
Phosphate-mmol/L 
(mean and std dev.) 
1.2±0.58 1.5±0.64 0.0051 
Parathyroid hormone-pmol/L 
(median and IQR) 
36.45(20.5-49.5) 49(27.5-91) 0.0166 
Albumin-g/L 
(mean and std dev.) 
39±4 35±5 ˂0.001 
 
C - reactive protein (CRP) was evaluated as an indicator of infection and 
inflammation.  It was not uniformly measured in all patients, with only 38 HD patients 
and 27 PD patients’ records yielding results, thus limiting the usefulness of this 
measure in this instance. The median CRP value was higher in the PD than the HD 
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group, with a value of 9mg/L (IQR 3- 20.5) as compared to 5.3mg/L (IQR 3-12); (p= 
0.1337). 
Sepsis was recorded in 12 patients in each group –the source of sepsis if known is 
indicated in the figure below. If multiple possible sources were recorded, each cause 
was reflected separately. 
 
  Figure 10: Source of sepsis  
 
One patient undergoing HD developed pure red call aplasia as a direct complication 
of erythropoietin use,. This patient had previously received Recormin® (epoetin beta) 
subcutaneously prior to the development of this complication. 
One patient undergoing HD had a cervical malignancy and one patient undergoing 
PD had an unspecified gastrointestinal malignancy. 
Figure 11 demonstrates the prevalence of use of an angiotensin receptor blocker 
(ARB) or an angiotensin converting enzyme inhibitor (ACE i) in these patient groups. 
Rates of use of an ACE inhibitor are similar in both of these groups - 62 % in the HD 
population and 59% in the PD population. Similar rates are also noted in the groups 
in terms of use of an ARB- 18% versus 17% respectively. 
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Figure 11: The use of an angiotensin receptor blocker (ARB) or an angiotensin converting enzyme 
inhibitor (ACE i) 
 
Hepatitis B and C status was reviewed; 5 patients demonstrated Hepatitis C 
seropositivity- 4 within the HD group and 1 within the PD group. Of these 5 patients, 
4 were currently undergoing or had recently completed interferon therapy. 
Furthermore, 3 of these patients had haemoglobin levels of less than 10g/dl.   
Hepatitis B was more prevalent and the interpretations of the serology results are 
reflected in figure 11. Co-infection with both Hepatitis B and C did not occur in any 
patient. As is evident in the figure below, acute hepatitis B was only present in a 
small proportion of the population sampled. It is important to note that 7 patients 
(11%) of the haemodialysis group had chronic replicating hepatitis B. These cases 
were confirmed by means of a liver biopsy. 
 
Figure 12: Hepatitis B status in dialysis patients 
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3.3 Comparison of Optimal versus Suboptimal Hb groups 
 
Of the 136 patients included in the study, 82 (60%) patients had optimal 
haemoglobin levels i.e. greater than 10g/dl, 53 patients (40%) had suboptimal levels 
and there was no result available for 1 patient. The average Hb levels in the optimal 
and suboptimal groups were 12.06 ± 1.65g/dl and 8.42 ± 2.08g/dl respectively. The 
wide variation of Hb levels in the suboptimal group is clearly evident in the scatter 
diagram below. 
  
Figure 13: Scatter plot demonstrating Hb distribution in suboptimal Hb group 
3.3.1 Demographics  
 
The following tables depict the race, gender and age distributions within the two 
populations. 
 
 
 
 
0
2
4
6
8
10
12
Hb- g/dl 
40 
 
 
Table 10: Race distribution in optimal and suboptimal Hb populations 
 
Total 
Optimal Hb 
(n=82) 
Suboptimal HB 
(n=53) 
Black 72(87%) 45(85%) 
White 5(6%) 2(3.7%) 
Indian 1(1.3%) 2(3.7%) 
Coloured 3(3.7%) 3(5.7%) 
Not stated 0 1(1.9%) 
 
Table 11: Gender distribution in optimal and suboptimal Hb populations  
 
Total 
Optimal Hb 
(n=82) 
Suboptimal HB 
(n=53) 
Male 50(61%) 27(51%) 
Female 31(38%) 26(49%) 
Not stated  1(1%) 0 
(p=0.38) 
Table 12: Mean age and standard deviation in optimal and suboptimal Hb populations  
 Optimal Hb 
(n=82) 
Suboptimal HB 
(n=53) 
Average age 
(years) 
47.1±12.18 43.83±14.41 
 
Among the demographic data, the average age is the only variable that 
demonstrated statistical significance in the comparison of the two groups, with the 
average age being greater in the optimal Hb group (p=0.026).  
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3.3.2 Duration and mode of dialysis 
 
Patients in the group classified as having an optimal haemoglobin level were on the 
chronic dialysis programme for a slightly longer period (39.15 ± 28.66 months) as 
compared to those in the suboptimal class (37.7 ± 28.82 months). This difference is 
not statistically significant (p=0.775). 
 While a higher proportion of patients on peritoneal dialysis had an optimal 
haemoglobin level (69%) as compared those on the haemodialysis programme 
(53%), this was not statistically significant (p= 0.07). 
 
3.3.3 Causes of CKD 
As is demonstrated in figure 13 below, in both cohorts of patients, the cause of CKD 
was unknown in majority of the patients – 69.5% in the optimum Hb group and 
58.5% in the suboptimal Hb group. When comparing the prevalence of each of the 
causes below in each of the Hb groups to the other causes, none demonstrated 
statistical significance. 
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Chi
2 
=7.050;dF=9;p value=0.632 
Figure 14: Causes of CKD 
 
3.3.4 Vascular Access in Haemodialysis subgroups   
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Figure 15: Comparison of types of vascular access in haemodialysis subgroups  
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As demonstrated graphically in figure 15 , a larger proportion of the optimum Hb 
group were dialysed by means of an arteriovenous fistula (41%) or a permanent 
cuffed vascular catheter(19%) as opposed to 36% and 8%  within the suboptimal Hb 
group respectively (p = 0.395). Also of note is the fact that a larger percentage within 
the suboptimal group were still dialyzing by means of a temporary venous catheter 
(28% versus 17%) (p = 0.2843).  
3.3.5 Management of anaemia 
 
Out of a possible 82 patients with a Hb level greater than 10g/dl,  69 patients (84%) 
were utilizing ESAs at the time of the study. This is almost identical to the group with 
the lower Hb level in which the rate of ESA usage was close to 85%.  The average 
dosage used in the patients  with a higher Hb was 47 884 ± 40 265 u/month as 
compared to 61 600 ± 45 328 u/month in the suboptimal group; however the 
difference in doses used was not of statistical difference (p=0.1062). 
Intravenous iron was used in 27 patients within the optimal Hb group (33%) and in 
12 patients in the suboptimal Hb group (23%), with higher average doses 
administered monthly to the suboptimal Hb group (283 ± 31mg/month versus 203 ± 
60mg/month). None of the comparisons with reference to the use of intravenous iron 
in these two groups yielded any statistically significant differences. 
The patient who required a transfusion for the management of pure red cell aplasia 
actually fell within the group with a optimal level of haemoglobin,following treatment. 
The other patient who received a transfusion on account of the complications of 
sepsis was in the suboptimal group. 
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3.3.6 Contributors to anaemia 
 
In terms of calcium homeostasis, the calcium levels were higher and the phosphate 
and parathyroid hormone levels were lower in the optimal Hb group as compared to 
the suboptimal Hb group. The albumin levels were higher in the optimal Hb group, 
but not to a statistically significant degree.  
Table 13: Comparison of biochemical parameters 
 OPTIMAL Hb SUBOPTIMAL 
Hb 
p 
value 
Corrected calcium-mmol/L 
(mean and std dev.) 
2.29±0.18 2.21±0.26 0.0454 
Phosphate-mmol/L 
(mean and std dev.) 
1.42±0.70 1.82±4.3 0.4081 
Parathyroid hormone-pmol/L 
(median and IQR) 
35.7 (22.2-75.2) 47 (37.3-87.5) 0.2668 
Albumin-g/L 
(mean and std dev.) 
38.8±4.52 36.2±5.25 0.0848 
 
CRP was measured in 38 patients in the optimal Hb group and in 27 patients in the 
suboptimal Hb group. The median in the optimal Hb group was 11mg/L (IQR 3.3-11) 
as compared to the suboptimal group 10mg/L (IQR 9.5-38) (p=0.868). 
Ferritin levels were also looked at as an indication of a proinflammatory state. Within 
the optimal Hb group the median ferritin levels was 282μg/L (IQR 148-550) as 
compared to higher level of 475μg/L (IQR 280-835) within the suboptimal Hb group. 
Higher doses of ESA’s were required among patients with higher ferritin levels as 
compared to those who had ferritin levels within the normal range i.e. ≤ 150 μg/l 
(53663  ± 42870 u/month versus 49480 ± 41495 u/month). However, this difference 
was not of statistical significance (p = 0.6647). 
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Sepsis was noted to be present in a greater proportion of the patients with lower 
haemoglobin levels (21% versus 14%); this difference was not statistically significant 
with a p value = 0.71. As per the chi-square test performed, there was no difference 
of statistical significance between the groups in terms of contributing aetiologies. 
 
Chi
2 
=4.584;dF=7;p value=0.71 
Figure 16: Aetiologies of sepsis in the cohort.  
 
 
Figure 17: use of ACE inhibitors and ARBS 
Rates of use of ACE inhibitors and ARBs were only marginally higher in the group of 
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19% receiving an ARB as compared to 58% and 17% respectively in the other group 
(p = 0.528), thus demonstrating that there is no impact of ACEi and ARBs on Hb 
levels. 
Of the 5 patients with Hepatitis C seropositivity, 3 fell within the suboptimal Hb group. 
All 3 of the cases were undergoing/had recently undergone pegylated interferon 
therapy. Hepatitis B serology results demonstrated no appreciable difference 
between the two groups with prevalence of both acute Hepatitis B and chronic 
replicating Hepatitis B being identical at 2% and 6% respectively. 
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CHAPTER 4: DISCUSSION 
 
4.1 Demography of chronic dialysis population 
 
According to the 2012 South African Renal Registry Annual Report, South Africa’s 
population is currently estimated at more than 52 million. Black persons constitute 
79.6% of the population; Coloureds make up 9.0%; Whites 8.8% and Indian/Asians 
2.5%. A vast majority of the country’s population (83.4 %) is dependent  on the 
public sector  for the provision of health care (77). 
 
Given South Africa’s racially discriminative history, many factors have to be 
considered when considering the epidemiology of disease profiles and utilization of 
health resources across this country. The Nephrology Unit in this study is located 
within Chris Hani Baragwanath Hospital, which is responsible for serving the densely 
populated, predominantly black population of Soweto, as well as smaller areas that 
were previously demarcated for white, coloured and Indian occupation.  More than 
90% of patients treated at this institution are black. This figure correlates with the fact 
that the vast majority of the chronic dialysis patients (88%) were black, with only 12% 
of the patients being of White, Coloured or Indian race. These figures differ 
significantly from the distribution by ethnicity contained within the 2012 South African 
Renal Registry Annual Report, with black patients reported to make up 51.2%, 
Whites 22.1%, Coloureds 14.5% and Indians/Asian 12.2% (77). However, these 
figures represent a combination of public sector and private sector patients on 
chronic dialysis. 
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There is a paucity of data on the conducting of dialysis in developing countries. This 
is largely attributed to the deficiency of renal registries, thereby limiting the ability to 
compare our data to other similar settings.  
 
According to the above 2012 report, the mean age for patients treated in the public 
sector in 2012 was 42.3 ± 13.6 years (77). The population looked at in this study was 
slightly older, with a mean of 45 ± 13 years. These figures are in keeping with the 
observations made that ESRD patients on dialysis are younger in the developing 
world where the delay in detection of kidney disease and the failure to institute 
suitable and timeous pre-emptive protective measures results in a more rapid 
deterioration of renal function and development of ESRD in younger patients. In 
India the reported average age for patients on chronic dialysis ranges between 47 - 
50.1years (78, 79). The average age in South Africa is significantly different to the 
average age of the patients undergoing dialysis in the United States, which has been 
progressively increasing over the last several decades. In 2000, the average age 
was approximately 62 years (80). In the United Kingdom the median age of all RRT 
patients was 58 years (81).  
 
A gender difference in the chronic dialysis population was not significant with 56.6% 
of the study population being male. This is similar to the 59.6% male predominance 
of patients with ESRD on RRT that was reported in the public sector countywide in 
2012 (77).  
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4.2 Causes of CKD 
 
The causes of CKD are often multifactorial, with multiple contributing pathologies. 
Only a renal biopsy may yield a conclusive diagnosis, however it is not often 
practical or possible in patients with CKD, on account of kidney size or complications 
of the kidney disease. The underlying cause of CKD is often established on the basis 
of a thorough history and examination of the patient and supporting laboratory and 
imaging investigations. The causes of ESRD in the chronic dialysis population does 
not accurately represent the aetiology of CKD in the population as a whole, as public 
sector state facilities offer RRT only to patients who are eligible for a transplant.  
 
The foremost causes of CKD in both developed and many developing countries are  
the chronic conditions of diabetes and hypertension, but glomerulonephritis and 
unknown causes are more common in  developing Asian and African nations (82). 
The spectrum of causes of ESRD in developing countries is changing but 
communicable diseases continue to be an immense problem in low-income 
countries, largely due to deficient sanitation, insufficient provision of potable water, 
and the presence of vector-borne diseases (5, 8, 83). The most common causes of 
ESRD in our study population in descending order were CKD of unknown aetiology, 
hypertension, primary glomerulonephritis, diabetes mellitus and chronic interstitial 
nephritis and polycystic kidney disease. This list is identical to the most common 
reported causes in ESRD in the 2012 South African Renal Registry Annual Report. 
Our findings were also similar to the findings published regarding the principal 
causes of ESRD in other developing countries such as India, which stated the 
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causes included chronic glomerulonephritis, diabetic nephropathy, chronic interstitial 
nephritis, and hypertensive nephrosclerosis (78, 83). 
  
As in most developing countries, more than 65% of patients in this study did not 
have an attributable cause of ESRD stated (78, 84). However, even by developing 
countries standards, this is a very large percentage. A study conducted on the Indian 
subcontinent reports that the percentage attributed to an undetermined causes 
ranged between 15-16.5% (82, 85). 
 
In a 2003 publication, Naicker stated that hypertension affects about 25% of the 
adult population and is the cause of ESRD in approximately 20% of patients on RRT 
in South Africa(86).This is concordant with the 17% of patients in this cohort in which 
hypertension was stated as the primary cause of CKD.  
 
The prevalence of diabetes mellitus is increasing worldwide, with the prevalence of  
diabetic nephropathy estimated to be 6–16% in Sub-Saharan Africa (8). Diabetes 
mellitus is the most common reason for initiation of RRT for ESRD in Europe, 
affecting more than 22% of the incident patients in a review of the European Renal 
Association and European Dialysis and Transplant Association database published 
in 2009 (87). 
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4.3 Mode of dialysis 
 
 
Patients on haemodialysis were on the chronic dialysis programme for a longer 
duration as compared to those on peritoneal dialysis. This trend was also 
demonstrated in a study undertaken at Groote Schuur Hospital in Cape Town, where 
it was noted that duration on dialysis therapy was significantly longer in HD patients 
as compared to those on PD (49.8 ± 71.5 months vs 14.5 ± 11.6 months; p = 0.001) 
(88). 
 
4.3.1 Haemodialysis 
 
56% of the study population was on the chronic haemodialysis programme. This is 
less than the national percentage  of 65% in the public sector in 2012 (77). The 
Fresenius Medical Care publication titled ‘ESRD Patients in 2011-A Global 
Perspective’ stated that at the end of year 2011, haemodialysis remained the most 
common treatment modality worldwide, with approximately 89% of all dialysis 
patients undergoing haemodialysis (89).  
 
4.3.1.1 Vascular Access  
 
Local and international guidelines state that patients should ideally have a functional 
permanent access at the time of dialysis therapy initiation and that arteriovenous 
fistula (AVF) is the vascular access of choice in haemodialysis patients (61, 90). The 
guidelines go on to state that if it is not possible to establish an AVF, the next access 
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route of choice is an AV graft. Generally, access via a cuffed tunnelled venous 
catheter is not advocated as a permanent means of vascular access.  
 
However, in contradiction to the recommendations, only 40% of patients that were 
being dialysed on the chronic dialysis programme at the time of the study were being 
dialyzed via an arteriovenous fistula. This is not significantly lower than the national 
percentage of 45.6% for patients in public health care in 2012 (77). 13% of the 
cohort was dialyzing via a cuffed venous catheter, either as a bridge until an AVF 
could be created or as a permanent means of vascular access. More distressing was 
the fact that a significantly higher proportion (more than 20%) were dialyzing by 
means of a temporary uncuffed venous catheter as compared to the national figure 
of 3.3% (77).  
 
The lack of compliance to the recommendations regarding vascular access means 
that these haemodialysis patients are more susceptible to complications such as 
infection, increased inflammation and blood loss- all contributing to the development 
and worsening of  anaemia. 
 
4.3.2 Peritoneal Dialysis 
 
The extent of peritoneal dialysis use is often influenced by government policy, 
availability of dialysis facilities, nephrology unit protocols and relative costs of 
obtaining supplies. In our setting, PD is often offered as the first option for dialysis 
due to lack of chronic haemodialysis slots and patient preference (84). The rates of 
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PD use varies worldwide, with the highest rates being in Mexico and Hong Kong 
(70.5% and 81.3% of all dialysis patients respectively), and with  much lower rates of 
5.3-19.3% being reported for the European countries of United Kingdom, the 
Netherlands, France, and Germany (91). The peritoneal dialysis rate at the 
nephrology unit at Baragwanath hospital lies midway between these two extremes at 
44%. 
 
4.4 Achievement of Hb targets 
 
 
Sixty percent of the study cohort had a Hb level greater than 10g/dl. This does not 
adhere to the recommendations set out in The Guidelines for the Optimal Care of 
Patients on Chronic Dialysis in South Africa, that states that “at least 75% of a cohort 
of patients should have haemoglobin levels of 11g/d and that no patient should have 
a haemoglobin level of less than 8g/dl.” (61)  Despite this, the 40% of patients with 
Hb levels below 10g/dl in our study is superior to the approximately 84% of patients 
in a Cape Town series of chronic dialysis patients (88). The investigators in this 
study attributed the low Hb to suboptimal ESA dosing and poor compliance to 
medication. 
These factors could also be contributing variables within our patient population. 
 
 
 
54 
 
 
4.4.1 Determinants and contributing factors  
4.4.1.1 Demographics 
 
Despite the fact that numerous studies stating that advanced age and black race is 
associated with greater rates of anaemia, this trend was not observed within this 
study population (28).  The average age within the suboptimal Hb group was actually 
lower. However, it was not possible to correlate the effects of ethnicity on anaemia, 
as the numbers of other race groups were too small to compare with the black group. 
4.4.1.2 Duration and mode of dialysis 
 
A study by Rocco et al stated that patients recently initiated dialysis therapy are less 
likely to meet KDOQI or KDIGO guidelines than patients with a longer duration of 
dialysis therapy (92). This finding was confirmed in our study with the optimal Hb 
group being on dialysis for a slightly longer duration.  As previously stated, PD is 
associated with a lower rate and lesser degree of anaemia. This is apparent in this 
study with a higher proportion of patients on peritoneal dialysis had an optimal 
haemoglobin level (69%) as compared those on the haemodialysis programme 
(53%), with the average Hb being significantly higher in the PD group  (p = 0.0144). 
The percentage of patients with an optimal Hb level correlates with the percentage 
described in a retrospective review of PD patients conducted at another nephrology 
unit at an academic centre in Johannesburg (84). 
  
Among the haemodialysis patients, the type of vascular access by which the patient 
was dialyzing was important. A study by Wasse et al looked at health status and 
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quality of life and its association with the vascular access type. Higher levels of 
perceived health status and quality of life were reported among patients who 
persistently dialysed through an AVF as opposed to a central venous catheter (93). 
According to the authors, this finding was attributable to greater adequacy of dialysis, 
less recirculation, and a more stable haemoglobin level and EPO dosing among AVF 
patients (93). Our study correlates with this finding, as demonstrated by the fact that 
the types of vascular access that were more conducive to maintaining optimal 
haemoglobin levels were an AVF and to lesser degree, a permanent cuffed vascular 
catheter. 
4.4.1.3 Cause of CKD 
 
According to the literature, patients with diabetes mellitus have significantly higher 
rates of anaemia at all stages of kidney disease but that was not the case in our 
study (94). Twenty percent of the patients in whom diabetes was listed as a cause 
had a suboptimal Hb level as compared to 40% of the chronic dialysis population as 
a whole. Also, the average haemoglobin level was higher among the diabetic 
patients than the non-diabetic patients, but not to a statistically significant degree 
(10.99 ± 2.69g/dl versus 10.63 ± 2.65g/dl; p = 0.701). 
 
4.4.1.4 Sepsis and Inflammation 
 
There were higher rates of sepsis noted within the cohort of patients with lower 
haemoglobin levels as described in other studies but in our study, the difference in 
rates of sepsis between the optimal and suboptimal groups was not significant. 
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According to a study conducted at Chris Hani Baragwanath Hospital nephrology unit 
in 1998-1999, there were a total of 34 peritonitis episodes affecting 18 patients over 
a period of 17 months (95)  The peritonitis rate reported at that time was similar to 
some countries in the developed world despite our patients’ poor socioeconomic 
circumstances (95, 96). However, in our study, the peritonitis rate was much higher 
with 10 PD patients affected by peritonitis in the period of January 2012 alone.  
Three parameters were looked at, in addition to the presence of sepsis, to indicate 
the presence of a proinflammatory state- CRP, ferritin levels and albumin levels. 
Some studies report that between 30 and 50% of chronic dialysis patients have 
raised levels of inflammatory markers such as C-reactive protein (97). Unfortunately 
on account of the very few patients having had a CRP level done during the study 
period, we could not accurately assess the prevalence of a raised CRP in our 
population. The CRP levels that were available were not significantly different 
between the optimal and suboptimal groups, but the ferritin levels were significantly 
higher in the suboptimal Hb group.  
 
A low serum albumin is thought to fairly accurately reflect an inflammatory state of 
moderate severity, and that a low serum albumin is more likely to be associated with 
greater rates and worse levels of anaemia (98, 99). Within this study population, 
lower levels of serum albumin were noted in the suboptimal Hb group as compared 
to the optimal Hb group, but the difference was not of statistical significance. The 
average levels of serum albumin concentration in the entire study population was 
comparable to the national average of 35.1 ± 12.2g/l (77). 
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As a consequence of a depressed cellular immunity, studies report an increased 
prevalence of tuberculosis (TB), especially extrapulmonary TB (97, 100). This trend 
however was not notable in our population, with only one patient on treatment for TB. 
 
4.4.1.5 Hepatitis C 
 
The World Health Organization (WHO) estimates that the worldwide prevalence of 
HCV infection averages 3% worldwide and it remains a frequent occurrence in 
patients receiving chronic dialysis both in developed and less-developed countries 
(101). The prevalence of Hep C antibody positivity in the dialysis population 
nationwide in South Africa in 2012 was 1.3% but at the nephrology unit being 
audited, a prevalence rate closer to that of the worldwide prevalence of 3.7% was 
noted. Despite the fact that only 5 patients had HCV, it is significant as 60% of these 
patients had a Hb level of less than 10g/dl. 
 
4.4.1.6 Hepatitis B 
 
Hepatitis B status had no statistically significant impact on Hb levels in our study. In 
2012, 1.8% of the patients on dialysis in South Africa had Hepatitis B, with 3.7% 
having immunity to the virus. The distinction between acute and chronic Hepatitis B 
was not made. In our study population 8% had chronic Hepatitis B, 2% had acute 
hepatitis B and 17.6% had immunity.  This situation is not optimal as all patients on 
haemodialysis should be vaccinated with the HBV vaccine according to the national 
South African Renal Society guidelines (61). 
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4.4.1.7 Medication use 
 
As described previously, the use of ACEi and ARBs prevents upregulation of EPO 
production and maturation of haematopoietic stem cells, thus reversibly inducing or 
worsening anaemia in patients with CKD. In our study population there was no 
significant difference in rates of usage of the RAS blocking agents between those 
patients who had a Hb level at target and those that did not. 
 
4.4.1.8 Calcium homeostasis 
 
The average calcium level in the study population lies within the recommended 
range of 2.01-2.5mmol/l as stated within the South African Renal Society guidelines, 
with a statistically significant lower concentration noted in the suboptimal Hb group 
(61). This finding, in conjunction with a higher phosphate concentration, was 
associated with a higher average concentration of PTH and greater rates of 
secondary hyperparathyroidism in this group. This is to be expected given the 
adverse effects of oversecretion of PTH on erythropoiesis. 
 
 
4.4.2 Management of anaemia 
4.4.2.1 ESAs 
 
As anaemia is associated with poor quality of life and an increased mortality in 
dialysis patients, many dialysis units utilize ESAs extensively. 90% of patients in a 
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multicentre Dutch study received ESAs, which is fairly similar to rates of usage in our 
cohort of patients (85%) (102). 
 
A Spanish multicentre comparative study comparing EPO use in PD and HD patients 
showed that PD patients had a reduced EPO requirement and less frequent 
administration than HD patients in order to obtain a similar optimal Hb level (103). A 
similar, statistically significant result was obtained in our study with 94% of the HD 
patients, as compared to 74% of the PD patients receiving regular ESA therapy. In a 
review of the PD patients at a Johannesburg academic nephrology unit spanning the 
five year period ranging 2000-2005 the average dose of EPO used was 2500 
iu/week (84). This is significantly lower than the average of 6930 iu/week that was 
used by the PD patients in our study. 
 
Higher doses of ESA’s were prescribed in patients with suboptimal Hb correction. 
This somewhat contradictory finding was also found in a 2012 study by Locatelli et 
al. The authors attributed this to treating doctors increasing ESA doses when the Hb 
is low and other factors such as inflammation (104). 
 
Higher doses of ESA’s were prescribed among patients with higher ferritin levels. 
This confirms the direct correlation between these two variables that is described in 
studies (104).  This is attributed to the impact of inflammation on iron metabolism via 
the creation of a functional iron blockade and subsequent ESA resistance (105). 
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4.4.2.2 Iron 
 
Intravenous iron sucrose was used in this nephrology unit. According to the KDIGO 
anaemia guidelines, all patients with a low Hb level and a serum ferritin level of less 
than 500ng/ml and a transferrin saturation of less than 30% should receive 
intravenous iron supplementation (68). However, based on the above 
recommendation, in our study less than half of the patients that should have been 
receiving IV iron were doing so. This likely contributed to the hyporesponsiveness to 
ESAs that is noted in a proportion of these patients. Varying rates of intravenous iron 
usage in dialysis patients have been reported. Bailie et al. found IV iron being 
prescribed to 20% of the patients with ESRD recruited from four academic 
nephrology practices in the United States (106). Our study showed that a higher 
percentage (29%) of the dialysis cohort was receiving IV iron. 
 
As per other studies and publications, the requirement for intravenous iron was 
higher in the HD group- likely attributable to the increased blood loss, lack of 
preservation of residual renal function and shorter red cell survival (18, 107). A study 
conducted in the United States demonstrated that a regimen of 100 mg of iron 
sucrose administered intravenously every second or fourth week was adequate to 
meet targets set out in the KDIGO guidelines (108). This is in keeping with the 
finding of our study that the average dosage in the haemodialysis group was 200mg 
per month. 
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4.5 Limitations  
 
As this was a retrospective review, there were inherent limitations of this study. The 
data collection was dependant on the information entered into the BART electronic 
database and the paper based records by the treating doctors, thus some 
information was lacking. The variables for which ‘not stated’ was the option selected 
on the data sheet were excluded in the analysis of the data which may have 
contributed to skewing of the data. A large proportion of the cohort did not have a 
cause of ESRD recorded. This is to be expected in a proportion of any chronic  
dialysis population but the percentage of patients with an unknown cause in our 
study was disproportionately large, as compared to studies conducted in other 
developing countries. Certain variables such as CRP levels were not measured / 
recorded in the majority of patients, leading to limited analysis of those results that 
were available. 
 
The study was a cross sectional one, therefor haemoglobin levels were only 
assessed at a single point in time. 
 
There were inadequate electronic and paper based records with reference to the 
exact numbers of patients that were being dialysed on the chronic haemodialysis 
programme. 
 
HIV disease is a significant contributor to the disease profiles in our setting. 
Therefore, the exclusion of HIV positive patients limited our study to a certain extent. 
Fortunately this subgroup of patients was small. 
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4.6 Conclusion 
 
Anaemia associated with CKD is a significant problem in the chronic dialysis 
populations at Chris Hani Baragwanath Hospital, with 40 % of patients achieving 
suboptimal Hb levels.  The prevalence and severity of anaemia is greater in the 
haemodialysis population, as compared to the PD population.  There are a variety of 
contributing factors including dialysis related factors (including the mode of dialysis, 
duration on dialysis and means of vascular access in haemodialysis patients); 
biochemistry related factors (such as secondary/tertiary hyperparathyroidism; sepsis 
and inflammation); and medication use. Rates of erythropoietin use in our population 
were comparable to international studies; however hyporesponsiveness to ESA 
therapy in our population is a concern based on the suboptimal rates of usage of 
intravenous iron. 
 
In conclusion, there is much room for improvement in the management of this grave 
consequence of ESRD by more stringent application of the available recent 
international and local guidelines. 
 
  
63 
 
 
CHAPTER 5: REFERENCES 
1. Diamandopoulos AA. Twelve centuries of nephrological writings in the Graeco-
Roman world of the Eastern Mediterranean (from Hippocrates to Aetius Amidanus). 
Nephrol Dial Transplant. 1999;(14):2-9. 
 
2. Eknoyan G. The Kidneys in the Bible: What Happened?  JASN. 2005;1(16):3464-71. 
 
3. Scarborough J. Galen's investigation of the kidney. Clio Medica. 1976;11:171. 
 
4. Black D. The story of nephrology. Journal of the Royal Society of Medicine. 
1980;73(7):514-8. 
 
5. Stanifer JW, Jing B, Tolan S, Helmke N, Mukerjee R, Naicker S, et al. The 
epidemiology of chronic kidney disease in sub-Saharan Africa: a systematic review and 
meta-analysis. The Lancet Global Health. 2014;2(3):e174-e81. 
 
6. Katz I, Mdleleni G, Shezi EZ, Butler O, Gerntholtz T. Strategies for the early detection 
and management of chronic kidney disease–tertiary and primary health care working 
together. CME: Renal Medicine. 2007;25(8):360-5. 
64 
 
 
 
7. Anand S, Kurella Tamura M, Chertow GM. The elderly patients on hemodialysis. The 
Italian journal of urology and nephrology. 2010;62(1):87-101.  
 
8. Naicker S. End-stage renal disease in sub-Saharan Africa. Ethnicity & Disease. 
2009;19(1 Suppl 1):S1-13-5.  
9. Naicker S. Burden of end-stage renal disease in sub-Saharan Africa. Clinical 
Nephrology. 2010;74:13-6. 
 
10. Veriava Y, du Toit E, Lawley CG, Milne FJ, Reinach SG. Hypertension as a cause of 
end-stage renal failure in South Africa. Journal of Human Hypertension. 1990;4(4):379-83.  
 
11. Statistical release P0309.3 Mortality and causes of death in South Africa, 2009: 
Findings from death notification. 
 
12. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia 
in chronic kidney disease: 2007 update of hemoglobin target. American Journal of Kidney 
Diseases. 2007;50(3):471-530. PubMed PMID: 17720528. Epub 2007/08/28.  
 
65 
 
 
13. IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: 
update 2000. American Journal of Kidney Diseases. 2001;37(1 Suppl 1):S182-238. PubMed 
PMID: 11229970. Epub 2001/03/07. 
 
14. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, 
classification, and stratification. American Journal of Kidney Diseases. 2002;39:S1-266.  
 
15. Grassmann A, Gioberge S, Moeller S, Brown G. ESRD patients in 2004: global 
overview of patient numbers, treatment modalities and associated trends. Nephrol Dial 
Transplant. 2005 Dec;20(12):2587-93. PubMed PMID: 16204281. Epub 2005/10/06.  
 
16. Sinnakirouchenan R, Holley JL. Peritoneal dialysis versus hemodialysis: risks, benefits, 
and access issues. Advances in Chronic Kidney Disease. 2011;18(6):428-32. PubMed PMID: 
22098661. Epub 2011/11/22.  
 
17. Grassmann A, Gioberge S, Moeller S, Brown G. End-stage renal disease: global 
demographics in 2005 and observed trends. Artificial Organs. 2006;30(12):895-7. PubMed 
PMID: 17181829. Epub 2006/12/22.  
 
66 
 
 
18. Ly J, Marticorena R, Donnelly S. Red blood cell survival in chronic renal failure. 
American Journal of Kidney Diseases. 2004;44(4):715-9. PubMed PMID: 15384023. Epub 
2004/09/24. 
 
 19. Rubin HR, Fink NE, Plantinga LC, Sadler JH, Kliger AS, Powe NR. Patient ratings of 
dialysis care with peritoneal dialysis vs hemodialysis. JAMA. 2004 11;291(6):697-703. 
PubMed PMID: 14871912. Epub 2004/02/12. 
 
 20. Chung SH, Noh H, Ha H, Lee HB. Optimal use of peritoneal dialysis in patients with 
diabetes. Peritoneal Dialysis International. 2009;29 Suppl 2:S132-4. PubMed PMID: 
19270202. Epub 2009/05/16. 
 
 21. Cameron JS, Hicks J. Sir Robert Christison (1797-1882): a neglected founder of 
nephrology. Journal of Nephrology. 2003;16(5):766-73. PubMed PMID: 14733427. Epub 
2004/01/22. 
 
 22. Cameron JS. Towards the millennium: a history of renal anaemia and the optimal use 
of epoetin. Nephrol Dial Transplant. 1999;14 Suppl 2:10-21. PubMed PMID: 10334663. Epub 
1999/05/20. 
 
67 
 
 
 23. de Benoist B, McLean E, Egli I, Cogswell M(eds). World Health Organization Global 
Database on Anaemia. Worldwide prevalence of Anaemia 1993-2005. 2008. 
 
24. Obrador GT, Pereira BJ. Anaemia of chronic kidney disease: an under-recognized and 
under-treated problem. Nephrol Dial Transplant. 2002;17(Suppl 11):44-6. PubMed PMID: 
12386258. Epub 2002/10/19. 
 
 25. Hsu CY, McCulloch CE, Curhan GC. Epidemiology of anemia associated with chronic 
renal insufficiency among adults in the United States: results from the Third National Health 
and Nutrition Examination Survey. JASN. 2002;13(2):504-10. PubMed PMID: 11805181. 
Epub 2002/01/24.  
 
26. Astor BC, Muntner P, Levin A, Eustace JA, Coresh J. Association of kidney function 
with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). 
Archives of Internal Medicine. 2002;162(12):1401-8. PubMed PMID: 12076240. Epub 
2002/06/22.  
 
27. McFarlane SI, Chen SC, Whaley-Connell AT, Sowers JR, Vassalotti JA, Salifu MO, et al. 
Prevalence and associations of anemia of CKD: Kidney Early Evaluation Program (KEEP) and 
National Health and Nutrition Examination Survey (NHANES) 1999-2004. American Journal 
of Kidney Diseases. 2008;51(4 Suppl 2):S46-55. PubMed PMID: 18359408. Epub 2008/04/11.  
68 
 
 
 
28. Nurko S. Anemia in chronic kidney disease: causes, diagnosis, treatment. Cleveland 
Clinic Journal of Medicine. 2006;73(3):289-97. PubMed PMID: 16548452. Epub 2006/03/22.  
 
29. de Francisco AL, Stenvinkel P, Vaulont S. Inflammation and its impact on anaemia in 
chronic kidney disease: from haemoglobin variability to hyporesponsiveness. NDT plus. 
2009;2(Suppl 1):i18-i26. PubMed PMID: 19461856. Pubmed Central PMCID: PMC2638546. 
Epub 2009/05/23. 
 
 30. Agarwal AK. Practical approach to the diagnosis and treatment of anemia associated 
with CKD in elderly. Journal of the American Medical Directors Association. 2006;7(9 
Suppl):S7-S12; quiz S7-21. PubMed PMID: 17098634. Epub 2006/11/14.  
 
31. Kalra PA. Lessons to be learned from recent studies of anaemia management in 
chronic kidney disease. Br J Cadiol. 2011;18:s1-s15. 
 
32. Tsagalis G. Renal anemia: a nephrologist's view. Hippokratia. 2011;15(Suppl 1):39-43. 
PubMed PMID: 21897757. Pubmed Central PMCID: PMC3139678. Epub 2011/09/08. 
 
69 
 
 
 33. Vos FE, Schollum JB, Coulter CV, Doyle TC, Duffull SB, Walker RJ. Red blood cell 
survival in long-term dialysis patients. American Journal of Kidney Diseases. 2011;58(4):591-
8. PubMed PMID: 21715072. Epub 2011/07/01. 
 
 34. Rao M, Pereira BJ. Optimal anemia management reduces cardiovascular morbidity, 
mortality, and costs in chronic kidney disease. Kidney International. 2005;68(4):1432-8. 
PubMed PMID: 16164618. Epub 2005/09/17. 
 
35. Kaw D, Malhotra D. Platelet dysfunction and end-stage renal disease. Seminars in 
dialysis. 2006;19(4):317-22. PubMed PMID: 16893410. Epub 2006/08/09.  
 
36. Tong EM, Nissenson AR. Erythropoietin and anemia. Seminars in nephrology. 
2001;21(2):190-203. PubMed PMID: 11245780. Epub 2001/03/14. 
 
 37. Maxwell PH, Osmond MK, Pugh CW, Heryet A, Nicholls LG, Tan CC, et al. 
Identification of the renal erythropoietin-producing cells using transgenic mice. Kidney 
International. 1993;44(5):1149-62. PubMed PMID: 8264149. Epub 1993/11/01.  
 
70 
 
 
38. Drüeke TB, Locatelli F, Clyne N, Eckardt K-U, Macdougall IC, Tsakiris D, et al. 
Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia. 
New England Journal of Medicine. 2006;355(20):2071-84. 
 
39. Jelkmann W. Regulation of erythropoietin production. J Physiol. 2011; 15(6):1251-8 
 
40. Wei L, Alhenc-Gelas F, Corvol P, Clauser E. The two homologous domains of human 
angiotensin I-converting enzyme are both catalytically active. The Journal of Biological 
Chemistry. 1991;266(14):9002-8. PubMed PMID: 1851160. Epub 1991/05/15. 
 
 41. Erdos EG. Angiotensin I converting enzyme and the changes in our concepts through 
the years. Hypertension. 1990;16(4):363-70. PubMed PMID: 2170273. Epub 1990/10/01.  
 
42. Rousseau A, Michaud A, Chauvet MT, Lenfant M, Corvol P. The hemoregulatory 
peptide N-acetyl-Ser-Asp-Lys-Pro is a natural and specific substrate of the N-terminal active 
site of human angiotensin-converting enzyme. The Journal of Biological Chemistry. 
1995;270(8):3656-61. PubMed PMID: 7876104. Epub 1995/02/24. 
  
43. Guigon M, Bonnet D. Inhibitory peptides in hematopoiesis. Experimental 
Hematology. 1995;23(6):477-81. PubMed PMID: 7768302. Epub 1995/06/01. 
71 
 
 
 
44. Azizi M, Ezan E, Nicolet L, Grognet JM, Menard J. High plasma level of N-acetyl-seryl-
aspartyl-lysyl-proline: a new marker of chronic angiotensin-converting enzyme inhibition. 
Hypertension. 1997;30(5):1015-9. PubMed PMID: 9369248. Epub 1997/11/22.  
 
45. Cheung W, Paik K, Mak R. Inflammation and cachexia in chronic kidney disease. 
Pediatr Nephrol. 2010;25(4):711-24. 
 
46. Kalantar-Zadeh K. Inflammatory marker mania in chronic kidney disease: pentraxins 
at the crossroad of universal soldiers of inflammation. CJASN. 2007;2(5):872-5. PubMed 
PMID: 17702716. Epub 2007/08/19. 
 
 47. Mueller HJ, Hahn, k., Schneider, H.W., Wanner, C., Mann, J. Contributing Factors to 
Hb-cycling in a large cohort of ESRD patients in Germany. American Society of Nephrology 
Annual Congress. 2006; San Diego, USA. 
 
48. Locatelli F, Andrulli S, Memoli B, Maffei C, Del Vecchio L, Aterini S, et al. Nutritional-
inflammation status and resistance to erythropoietin therapy in haemodialysis patients. 
Nephrol Dial Transplant. 2006;21(4):991-8. PubMed PMID: 16384825. Epub 2005/12/31.  
 
72 
 
 
49. Al-Khoury S, Afzali B, Shah N, Thomas S, Gusbeth-Tatomir P, Goldsmith D, et al. 
Diabetes, kidney disease and anaemia: time to tackle a troublesome triad? International 
Journal of Clinical Practice. 2007;61(2):281-9. PubMed PMID: 17263715. Epub 2007/02/01.  
 
50. Barany P, Divino Filho JC, Bergstrom J. High C-reactive protein is a strong predictor of 
resistance to erythropoietin in hemodialysis patients. American Journal of Kidney Diseases. 
1997;29(4):565-8. PubMed PMID: 9100046. Epub 1997/04/01. 
 
 51. Brancaccio D, Cozzolino M, Gallieni M. Hyperparathyroidism and anemia in uremic 
subjects: a combined therapeutic approach. JASN. 2004;15(Suppl 1):S21-4. PubMed PMID: 
14684666. Epub 2003/12/20.  
 
52. Eschbach JW, Adamson JW. Recombinant human erythropoietin: implications for 
nephrology. American Journal of Kidney Diseases. 1988;11(3):203-9. PubMed PMID: 
3278599. Epub 1988/03/01. 
 
 53. Zingraff J, Drueke T, Marie P, Man NK, Jungers P, Bordier P. Anemia and secondary 
hyperparathyroidism. Archives of Internal Medicine. 1978;138(11):1650-2. PubMed PMID: 
718313. Epub 1978/11/01. 
 
73 
 
 
 54. Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, et al. Mortality 
Risk for Dialysis Patients With Different Levels of Serum Calcium, Phosphorus, and PTH: The 
Dialysis Outcomes and Practice Patterns Study (DOPPS). American Journal of Kidney 
Diseases.52(3):519-30. 
 
55. Schmidt RJ, Dalton CL. Treating anemia of chronic kidney disease in the primary care 
setting: cardiovascular outcomes and management recommendations. Osteopathic 
Medicine and Primary Care. 2007;1:14. PubMed PMID: 17910755. Pubmed Central PMCID: 
PMC2147011. Epub 2007/10/04. 
 
56. Valderrabano F, Jofre R, Lopez-Gomez JM. Quality of life in end-stage renal disease 
patients. American Journal of Kidney Diseases. 2001;38(3):443-64. PubMed PMID: 
11532675. Epub 2001/09/05. 
 
 57. Pisoni RL, Bragg-Gresham JL, Young EW, Akizawa T, Asano Y, Locatelli F, et al. Anemia 
management and outcomes from 12 countries in the Dialysis Outcomes and Practice 
Patterns Study (DOPPS). American Journal of Kidney Diseases. 2004;44(1):94-111. PubMed 
PMID: 15211443. Epub 2004/06/24.  
 
74 
 
 
58. Mohanram A, Zhang Z, Shahinfar S, Keane WF, Brenner BM, Toto RD. Anemia and 
end-stage renal disease in patients with type 2 diabetes and nephropathy. Kidney 
International. 2004;66(3):1131-8. PubMed PMID: 15327408. Epub 2004/08/26. 
 
 59. Painter P, Moore G, Carlson L, Paul S, Myll J, Phillips W, et al. Effects of exercise 
training plus normalization of hematocrit on exercise capacity and health-related quality of 
life. American Journal of Kidney Diseases. 2002;39(2):257-65. PubMed PMID: 11840365. 
Epub 2002/02/13.  
 
60. Adamson JW. Hyporesponsiveness to erythropoiesis stimulating agents in chronic 
kidney disease: the many faces of inflammation. Advances in Chronic Kidney Disease. 
2009;16(2):76-82. PubMed PMID: 19233066. 
 
61. Guidelines for the Optimal Care of Patients on Chronic Dialysis in South Africa. South 
African Renal Society. http://www.kznhealth.gov.za/medicine/sars. 
 
62. Hayat A, Haria D, Salifu MO. Erythropoietin stimulating agents in the management of 
anemia of chronic kidney disease. Patient Preference and Adherence. 2008;2:195-200. 
PubMed PMID: 19920963. Pubmed Central PMCID: PMC2769266. Epub 2008/01/01.  
 
75 
 
 
63. Locatelli F, Olivares J, Walker R, Wilkie M, Jenkins B, Dewey C, et al. Novel 
erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. 
Kidney International. 2001;60(2):741-7. PubMed PMID: 11473657. Epub 2001/07/28.  
64. Mason-Garcia M, Beckman BS, Brookins JW, Powell JS, Lanham W, Blaisdell S, et al. 
Development of a new radioimmunoassay for erythropoietin using recombinant 
erythropoietin. Kidney International. 1990;38(5):969-75. PubMed PMID: 2266682. Epub 
1990/11/01. 
 
 65. Locatelli F, Del Vecchio L. Erythropoiesis-Stimulating Agents in Renal Medicine. The 
Oncologist.  2011;16(suppl 3):19-24. 
 
66. Foley RN. Emerging erythropoiesis-stimulating agents. Nat Rev Nephrol. 
2010;6(4):218-23. 
 
67. van der Putten K, Braam B, Jie KE, Gaillard CAJM. Mechanisms of Disease: 
erythropoietin resistance in patients with both heart and kidney failure. Nat Clin Pract Neph. 
2008;4(1):47-57. 
 
76 
 
 
68. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO 
Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Inter. 2012;2(Suppl 
2012):279-335. 
 
69. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia 
in chronic kidney disease: 2007 update of hemoglobin target. American Journal of Kidney 
Diseases. 2007;50(3):471-530. PubMed PMID: 17720528. Epub 2007/08/28.  
 
 
70. Lo WK. Latest strategy in renal anemia management in peritoneal dialysis patients. 
Peritoneal Dialysis International. 2008;28 Suppl 3:S76-80. PubMed PMID: 18552270. Epub 
2008/09/20. 
 
 71. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al. Correction of 
anemia with epoetin alfa in chronic kidney disease. The New England Journal of Medicine. 
2006;355(20):2085-98. PubMed PMID: 17108343. Epub 2006/11/17. 
 
 72. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, et al. A 
trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. The New England 
Journal of Medicine. 2009;361(21):2019-32. PubMed PMID: 19880844. Epub 2009/11/03.  
77 
 
 
 
73. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, et al. 
Normalization of hemoglobin level in patients with chronic kidney disease and anemia. The 
New England Journal of Medicine. 2006;355(20):2071-84. PubMed PMID: 17108342. Epub 
2006/11/17.  
 
74. FDA. FDA Strengthens Boxed Warnings, Approves Other Safety Labeling Changes for 
Erythropoiesis-Stimulating Agents (ESAs). 2007. 
 
75. Cameron JS. European best practice guidelines for the management of anaemia in 
patients with chronic renal failure. Nephrol Dial Transplant. 1999;14(Suppl 2)61-5. PubMed 
PMID: 10334669. Epub 1999/05/20.  
 
76. Locatelli F, Aljama P, Barany P, Canaud B, Carrera F, Eckardt KU, et al. Revised 
European best practice guidelines for the management of anaemia in patients with chronic 
renal failure. Nephrol Dial Transplant. 2004;19(Suppl 2)1-47. PubMed PMID: 15206425. 
Epub 2004/06/23.  
 
78 
 
 
77. Davids MRM, Marais N, Jacobs JC. South African Renal Registry Annual Report 2012. 
South  African Renal Society. http:// sa-renalsociety.org/Registry2012.pdf. Accessed October 
2014. 
 
78. Modi GK, Jha V. The incidence of end-stage renal disease in India: A population-
based study. Kidney International. 2006;70(12):2131-3. 
 
79. Rajapurkar MM, John GT, Kirpalani AL, Abraham G, Agarwal SK, Almeida AF, et al. 
What do we know about chronic kidney disease in India: first report of the Indian CKD 
registry. BMC Nephrology. 2012;13:10. PubMed PMID: 22390203. Pubmed Central PMCID: 
PMC3350459. Epub 2012/03/07. 
 
 80. Hansberry MR, Whittier WL, Krause MW. The elderly patient with chronic kidney 
disease. Advances in Chronic Kidney Disease. 2005;12(1):71-7. PubMed PMID: 15719336. 
Epub 2005/02/19. 
 
 81. The Renal Association:UK Renal Registry. The Fifteenth Annual Report. 2012. 
http://renalreg.org/reports/2012-the-fifteenth-annual-report.  Accessed 12/10/2014 
 
79 
 
 
82. Jha V. Current status of end-stage renal disease care in India and Pakistan. Kidney 
Inter Suppl. 2013;3(2):157-60. 
 
83. Barsoum RS. Chronic Kidney Disease in the Developing World. New England Journal 
of Medicine. 2006;354(10):997-9. PubMed PMID: 16525136. 
 
84. Naidoo S, Naicker S, Malgas S, Paget G, Wadee S, Fabian J. Peritoneal dialysis in 
South Africa—a single centre experience. Indian Journal of Peritoneal Dialysis. 2008;13:18-
21. 
 
85. Jayatilake N, Mendis S, Maheepala P, Mehta FR. Chronic kidney disease of uncertain 
aetiology: prevalence and causative factors in a developing country. BMC Nephrology. 
2013;14:180. PubMed PMID: 23981540. Pubmed Central PMCID: PMC3765913. Epub 
2013/08/29.  
 
86. Naicker S. End-stage renal disease in sub-Saharan and South Africa. Kidney Int Suppl. 
2003;(83):S119-22. PubMed PMID: 12864889. Epub 2003/07/17. 
 
80 
 
 
 87. Zoccali C, Kramer A, Jager K. The databases: renal replacement therapy since 1989--
the European Renal Association and European Dialysis and Transplant Association (ERA-
EDTA). CJASN. 2009;4 (Suppl 1):S18-22. PubMed PMID: 19996000. Epub 2010/01/09.  
 
88. Okpechi IG, Nthite T, Swanepoel CR. Health-related quality of life in patients on 
hemodialysis and peritoneal dialysis. Saudi Journal of Kidney Diseases and Transplantation. 
2013;24(3):519-26. PubMed PMID: 23640624. Epub 2013/05/04.  
 
89. Fresenius Medical Care. ESRD Patients in 2012. A Global Perspective. Germany; 2012 
http://.vision-fmc.com/files/pdf_2/ESRD_Patients_2012.pdf. Accessed  March 2014 
 
90. Clinical Practice Guidelines for Vascular Access. American Journal of Kidney Diseases. 
2006;48(Suppl 1):S176-S247. 
 
91. Lameire N, Van Biesen W. Epidemiology of peritoneal dialysis: a story of believers 
and nonbelievers. Nat Rev Nephrol. 2010;6(2):75-82. PubMed PMID: 20010897. Epub 
2009/12/17.  
 
81 
 
 
92. Rocco MV, Bedinger MR, Milam R, Greer JW, McClellan WM, Frankenfield DL. 
Duration of dialysis and its relationship to dialysis adequacy, anemia management, and 
serum albumin level. American Journal of Kidney Diseases. 2001;38(4):813-23. 
 
93. Wasse H, Kutner N, Zhang R, Huang Y. Association of Initial Hemodialysis Vascular 
Access with Patient-Reported Health Status and Quality of Life. Clinical Journal of the 
American Society of Nephrology. 2007;2(4):708-14. 
 
94. El-Achkar TM, Ohmit SE, McCullough PA, Crook ED, Brown WW, Grimm R, et al. 
Higher prevalence of anemia with diabetes mellitus in moderate kidney insufficiency: The 
Kidney Early Evaluation Program. Kidney International. 2005;67(4):1483-8. PubMed PMID: 
15780101. Epub 2005/03/23.  
 
95. Katz IJ, Sofianou L, Hopley M. An African community-based chronic ambulatory 
peritoneal dialysis programme. Nephrol Dial Transplant. 2001;16(12):2395-400. PubMed 
PMID: 11733632. Epub 2001/12/06.  
 
96. Jager KJ, Merkus MP, Dekker FW, Boeschoten EW, Tijssen JGP, Stevens P, et al. 
Mortality and technique failure in patients starting chronic peritoneal dialysis: Results of the 
Netherlands Cooperative Study on the Adequacy of Dialysis. Kidney International. 
1999;55(4):1476-85. 
82 
 
 
 
97. Jofre R, Rodriguez-Benitez P, Lopez-Gomez JM, Perez-Garcia R. Inflammatory 
syndrome in patients on hemodialysis. JASN. 2006;17(12 Suppl 3):S274-80. PubMed PMID: 
17130274. Epub 2006/11/30.  
 
98. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to 
inflammation. The New England Journal of Medicine. 1999;340(6):448-54. PubMed PMID: 
9971870. Epub 1999/02/11.  
 
99. Agarwal R, Davis JL, Smith L. Serum albumin is strongly associated with 
erythropoietin sensitivity in hemodialysis patients. CJASN. 2008;3(1):98-104. PubMed PMID: 
18045859. Pubmed Central PMCID: PMC2390989. Epub 2007/11/30.  
 
100. Hussein MM, Mooij JM, Roujouleh H. Tuberculosis and Chronic Renal Disease. 
Seminars in Dialysis. 2003;16(1):38-44. 
 
101. Fabrizi F. Hepatitis C virus infection and dialysis: 2012 update. ISRN Nephrology. 
2013;159760. PubMed PMID: 24959533. Pubmed Central PMCID: PMC4045425. Epub 
2013/01/01. 
 
83 
 
 
 102. Suttorp MM, Hoekstra T, Rotmans JI, Ott I, Mittelman M, Krediet RT, et al. 
Erythropoiesis-stimulating agent resistance and mortality in hemodialysis and peritoneal 
dialysis patients. BMC Nephrology. 2013;14:200. PubMed PMID: 24066978. Pubmed Central 
PMCID: PMC3849281. Epub 2013/09/27.  
 
103. Coronel F, Herrero JA, Montenegro J, Fernandez C, Gandara A, Conesa J, et al. 
Erythropoietin requirements: a comparative multicenter study between peritoneal dialysis 
and hemodialysis. Journal of Nephrology. 2003;16(5):697-702. PubMed PMID: 14733416. 
Epub 2004/01/22. 
 
104. Locatelli F, Altieri P, Andrulli S, Sau G, Bolasco P, Pedrini LA, et al. Predictors of 
haemoglobin levels and resistance to erythropoiesis-stimulating agents in patients treated 
with low-flux haemodialysis, haemofiltration and haemodiafiltration: results of a 
multicentre randomized and controlled trial. Nephrol Dial Transplant. 2012;27(9):3594-600. 
PubMed PMID: 22622452. Pubmed Central PMCID: PMC3433772. Epub 2012/05/25.  
 
105. El-Khatib MT. The role of inflammation on iron and erythropoietin resistance. JNRT. 
2009;2(2):45-54. 
 
84 
 
 
106. Bailie GR, Eisele G, Liu L, Roys E, Kiser M, Finkelstein F, et al. Patterns of medication 
use in the RRI-CKD study: focus on medications with cardiovascular effects. Nephrology 
Dialysis Transplantation. 2005;20(6):1110-5. 
 
107. Raja R, Bloom E, Goldstein M, Johnson R. Erythropoietin with oral iron in peritoneal 
and hemodialysis patients. A comparison in an inner city population. ASAIO Journal. 1993 
Jul-Sep;39(3):M578-80. PubMed PMID: 8268603. Epub 1993/07/01.  
 
108. Nguyen TV. Intravenous iron requirement in adult hemodialysis patients. Dialysis & 
Transplantation. 2006;35(9):555-6. 
 
85 
 
 
CHAPTER 6: APPENDICES 
Appendix A: Ethics clearance certificate
 
86 
 
 
Appendix B: Data Collection Sheet
 
87 
 
 
 
88 
 
 
 
89 
 
 
 
 
90 
 
 
Appendix C: Permissions 
Figure 1 
ELSEVIER LICENSE 
TERMS AND CONDITIONS 
 
 
 
This is a License Agreement between Reena Kara ("You") and Elsevier ("Elsevier") provided by Copyright 
Clearance Center ("CCC"). The license consists of your order details, the terms and conditions provided by 
Elsevier, and the payment terms and conditions. 
All payments must be made in full to CCC. For payment instructions, please see 
information listed at the bottom of this form. 
Supplier Elsevier Limited 
The Boulevard,Langford Lane 
Kidlington,Oxford,OX5 1GB,UK 
Registered Company 
Number 
1982084 
Customer name Reena Kara 
Customer address Sandton 
  Johannesburg, 2196 
License number 3478170968610 
License date Sep 29, 2014 
Licensed content publisher Elsevier 
Licensed content publication American Journal of Kidney Diseases 
Licensed content title Prevalence and Associations of Anemia of CKD: Kidney Early 
Evaluation Program (KEEP) and National Health and Nutrition 
Examination Survey (NHANES) 1999-2004 
Licensed content author Samy I. McFarlane,Shu-Cheng Chen,Adam T. Whaley-
Connell,James R. Sowers,Joseph A. Vassalotti,Moro O. 
Salifu,Suying Li,Changchun Wang,George Bakris,Peter A. 
McCullough,Allan J. Collins,Keith C. Norris 
Licensed content date April 2008 
Licensed content volume 
number 
51 
Licensed content issue 
number 
4 
Number of pages 10 
Start Page S46 
End Page S55 
91 
 
 
Type of Use reuse in a thesis/dissertation 
Intended publisher of new 
work 
other 
Portion figures/tables/illustrations 
Number of 
figures/tables/illustrations 
1 
Format print 
Are you the author of this 
Elsevier article? 
No 
Will you be translating? No 
Title of your 
thesis/dissertation 
Haemoglobin levels in the chronic dialysis population in the 
Nephrology Unit at Chris Hani Baragwanath Academic 
Hospital 
 
  
92 
 
 
Figure 2 
ELSEVIER LICENSE 
TERMS AND CONDITIONS 
 
 
 
This is a License Agreement between Reena Kara ("You") and Elsevier ("Elsevier") provided by Copyright 
Clearance Center ("CCC"). The license consists of your order details, the terms and conditions provided by 
Elsevier, and the payment terms and conditions. 
All payments must be made in full to CCC. For payment instructions, please see 
information listed at the bottom of this form. 
Supplier Elsevier Limited 
The Boulevard,Langford Lane 
Kidlington,Oxford,OX5 1GB,UK 
Registered Company Number 1982084 
Customer name Reena Kara 
Customer address Sandton 
  Johannesburg, 2196 
License number 3478180393932 
License date Sep 29, 2014 
Licensed content publisher Elsevier 
Licensed content publication Journal of the American Medical Directors Association 
Licensed content title Practical Approach to the Diagnosis and Treatment of 
Anemia Associated With CKD in Elderly 
Licensed content author Anil K. Agarwal 
Licensed content date November 2006 
Licensed content volume 
number 
7 
Licensed content issue number 9 
Number of pages 6 
Start Page S7 
End Page S12 
Type of Use reuse in a thesis/dissertation 
Intended publisher of new work other 
Portion figures/tables/illustrations 
Number of 
figures/tables/illustrations 
1 
Format print 
93 
 
 
Are you the author of this 
Elsevier article? 
No 
Will you be translating? No 
Title of your thesis/dissertation Haemoglobin levels in the chronic dialysis population in 
the Nephrology Unit at Chris Hani Baragwanath 
Academic Hospital 
 
94 
 
 
Figure 3 
JOHN WILEY AND SONS LICENSE 
TERMS AND CONDITIONS 
 
 
 
 
This is a License Agreement between Reena Kara ("You") and John Wiley and Sons 
("John Wiley and Sons") provided by Copyright Clearance Center ("CCC"). The 
license consists of your order details, the terms and conditions provided by John Wiley 
and Sons, and the payment terms and conditions. 
All payments must be made in full to CCC. For payment instructions, please see 
information listed at the bottom of this form. 
License Number 3478181284851 
License date Sep 29, 2014 
Licensed content publisher John Wiley and Sons 
Licensed content 
publication 
Journal of Physiology 
Licensed content title Regulation of erythropoietin production 
Licensed copyright line © 2011 The Author. Journal compilation © 2011 The 
Physiological Society 
Licensed content author Wolfgang Jelkmann 
Licensed content date Mar 14, 2011 
Start page 1251 
End page 1258 
Type of use Dissertation/Thesis 
 
Requestor type University/Academic 
Format Print 
Portion Figure/table 
Number of figures/tables 1 
Original Wiley figure/table 
number(s) 
Figure 1 
Will you be translating? No 
Title of your thesis / 
dissertation 
Haemoglobin levels in the chronic dialysis population in the 
Nephrology Unit at Chris Hani Baragwanath Academic Hospital 
 
 
 
 
95 
 
 
Table 3 
ELSEVIER LICENSE 
TERMS AND CONDITIONS 
 
 
 
This is a License Agreement between Reena Kara ("You") and Elsevier ("Elsevier") provided by Copyright 
Clearance Center ("CCC"). The license consists of your order details, the terms and conditions provided by 
Elsevier, and the payment terms and conditions. 
All payments must be made in full to CCC. For payment instructions, please see 
information listed at the bottom of this form. 
Supplier Elsevier Limited 
The Boulevard,Langford Lane 
Kidlington,Oxford,OX5 1GB,UK 
Registered Company Number 1982084 
Customer name Reena Kara 
Customer address Sandton 
  Johannesburg, 2196 
License number 3478690869437 
License date Sep 29, 2014 
Licensed content publisher Elsevier 
Licensed content publication American Journal of Kidney Diseases 
Licensed content title Part 4. Definition and Classification of Stages of Chronic 
Kidney Disease 
Licensed content author None 
Licensed content date February 2002 
Licensed content volume 
number 
39 
Licensed content issue number 2 
Number of pages 30 
Start Page S46 
End Page S75 
Type of Use reuse in a thesis/dissertation 
Intended publisher of new work Other 
Portion figures/tables/illustrations 
Number of 
figures/tables/illustrations 
1 
Format Print 
96 
 
 
Are you the author of this 
Elsevier article? 
No 
Will you be translating? No 
Title of your thesis/dissertation Haemoglobin levels in the chronic dialysis population in 
the Nephrology Unit at Chris Hani Baragwanath 
Academic Hospital 
 
  
97 
 
 
Appendix D: Plagiarism report 
 
 
